[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fu9VKKPrHJ5mytG0iaTM3zkDogskdaleiP4Xi7kRyzWk":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":8,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":34,"phaseBuckets":61,"rows":68},"Ferring Pharmaceuticals",[4],249,false,8,93,1219118,41,[13,15,18,21,24,27,29,31],{"name":14,"count":11},"Prostate Cancer",{"name":16,"count":17},"Infertility",32,{"name":19,"count":20},"Nocturia",17,{"name":22,"count":23},"Ulcerative Colitis",15,{"name":25,"count":26},"Cervical Ripening",9,{"name":28,"count":8},"Infertility, Female",{"name":30,"count":8},"Crohn's Disease",{"name":32,"count":33},"Controlled Ovarian Stimulation",5,[35,40,45,50,53,57],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT06561958","Prospective, Multi-centre, Non-Interventional Study to Investigate the Effectiveness of REKOVELLE® for Ovarian Stimulation for Asian Women in Real World Settings","2027-05-01","REKOVELLE",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT04113382","Study Assessing CLENPIQ as Bowel Preparation for Pediatric Colonoscopy","2027-06","CLENPIQ",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT06510374","Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer","2028-06-30","Nadofaragene Firadenovec",{"nctId":51,"briefTitle":52,"date":48,"intervention":49},"NCT06545955","A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer",{"nctId":54,"briefTitle":55,"date":56,"intervention":49},"NCT06668493","Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis","2029-11-30",{"nctId":58,"briefTitle":59,"date":56,"intervention":60},"NCT05704244","Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC)","FE 999326",[62,63,64,65,66,67],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[69,126,144,162,180,201,223,241,272,332,399,463,509,555,592,614,639,663,681,699,717,735,753,780,798,816,834,860,878,900,918,936,997,1045,1093,1134,1160,1203,1239,1271,1303,1337,1359,1388,1427,1449,1485,1517,1551,1573,1607,1629,1654,1681,1699,1717,1740,1758,1783,1801,1827,1845,1868,1892,1910,1936,1954,1978,1996,2022,2040,2064,2082,2106,2124,2146,2173,2191,2209,2227,2253,2271,2295,2320,2338,2363,2388,2406,2429,2447,2471,2494,2512,2530,2555,2573,2598,2651,2695,2730,2768,2786,2810,2828,2846,2864,2892,2910,2928,2946,2964,2982,3008,3026,3044,3062,3083,3108,3131,3153,3177,3203,3221,3239,3262,3283,3301,3319,3343,3371,3389,3407,3425,3443,3461,3485,3503,3521,3545,3563,3581,3603,3626,3644,3669,3693,3717,3735,3760,3778,3802,3827,3845,3869,3895,3913,3935,4207,4329,4425,4465,4508,4543,4583,4622,4656,4684,4717,4748,4771,4794,4818,4840,4864,4882,4906,4930,4948,4970],{"intervention":49,"totalTrials":70,"cells":71},4,{"EARLY_PHASE1":72,"PHASE1":75,"PHASE2":77,"PHASE3":88,"PHASE4":109,"NA":124},{"trials":73,"activeCount":74},[],0,{"trials":76,"activeCount":74},[],{"trials":78,"activeCount":87,"soonestReadout":56},[79],{"nctId":54,"briefTitle":55,"status":80,"phases":81,"primaryCompletion":56,"completion":56,"start":82,"enrollment":83,"conditions":84,"interventions":86},"RECRUITING",[63,64],"2025-06-12",20,[85],"Low-grade Upper Tract Urothelial Carcinoma",[49],1,{"trials":89,"activeCount":108,"soonestReadout":48},[90,98],{"nctId":46,"briefTitle":47,"status":80,"phases":91,"primaryCompletion":48,"completion":92,"start":93,"enrollment":94,"conditions":95,"interventions":97},[65],"2031-06-30","2024-10-01",454,[96],"Intermediate Risk Non-Muscle Invasive Bladder Cancer",[49],{"nctId":51,"briefTitle":52,"status":80,"phases":99,"primaryCompletion":48,"completion":100,"start":93,"enrollment":101,"conditions":102,"interventions":104},[65],"2030-12-31",250,[103],"Non-muscle Invasive Bladder Cancer With Carcinoma in Situ",[49,105,106,107],"Gemcitabine","Docetaxel","Pembrolizumab",2,{"trials":110,"activeCount":74},[111],{"nctId":112,"briefTitle":113,"status":114,"phases":115,"primaryCompletion":116,"completion":116,"start":117,"enrollment":74,"conditions":118,"interventions":122},"NCT06390111","A Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS ± High-grade Ta\u002FT1 and no Complete Response to First Nadofaragene Firadenovec Dose.","WITHDRAWN",[66],"2026-07-31","2024-06-17",[119,120,121],"Bladder Cancer","Ta\u002FT1","CIS",[123],"nadofaragene firadenovec",{"trials":125,"activeCount":74},[],{"intervention":105,"totalTrials":87,"cells":127},{"EARLY_PHASE1":128,"PHASE1":130,"PHASE2":132,"PHASE3":134,"PHASE4":140,"NA":142},{"trials":129,"activeCount":74},[],{"trials":131,"activeCount":74},[],{"trials":133,"activeCount":74},[],{"trials":135,"activeCount":87,"soonestReadout":48},[136],{"nctId":51,"briefTitle":52,"status":80,"phases":137,"primaryCompletion":48,"completion":100,"start":93,"enrollment":101,"conditions":138,"interventions":139},[65],[103],[49,105,106,107],{"trials":141,"activeCount":74},[],{"trials":143,"activeCount":74},[],{"intervention":106,"totalTrials":87,"cells":145},{"EARLY_PHASE1":146,"PHASE1":148,"PHASE2":150,"PHASE3":152,"PHASE4":158,"NA":160},{"trials":147,"activeCount":74},[],{"trials":149,"activeCount":74},[],{"trials":151,"activeCount":74},[],{"trials":153,"activeCount":87,"soonestReadout":48},[154],{"nctId":51,"briefTitle":52,"status":80,"phases":155,"primaryCompletion":48,"completion":100,"start":93,"enrollment":101,"conditions":156,"interventions":157},[65],[103],[49,105,106,107],{"trials":159,"activeCount":74},[],{"trials":161,"activeCount":74},[],{"intervention":107,"totalTrials":87,"cells":163},{"EARLY_PHASE1":164,"PHASE1":166,"PHASE2":168,"PHASE3":170,"PHASE4":176,"NA":178},{"trials":165,"activeCount":74},[],{"trials":167,"activeCount":74},[],{"trials":169,"activeCount":74},[],{"trials":171,"activeCount":87,"soonestReadout":48},[172],{"nctId":51,"briefTitle":52,"status":80,"phases":173,"primaryCompletion":48,"completion":100,"start":93,"enrollment":101,"conditions":174,"interventions":175},[65],[103],[49,105,106,107],{"trials":177,"activeCount":74},[],{"trials":179,"activeCount":74},[],{"intervention":60,"totalTrials":87,"cells":181},{"EARLY_PHASE1":182,"PHASE1":184,"PHASE2":186,"PHASE3":188,"PHASE4":197,"NA":199},{"trials":183,"activeCount":74},[],{"trials":185,"activeCount":74},[],{"trials":187,"activeCount":74},[],{"trials":189,"activeCount":87,"soonestReadout":56},[190],{"nctId":58,"briefTitle":59,"status":191,"phases":192,"primaryCompletion":56,"completion":56,"start":193,"enrollment":194,"conditions":195,"interventions":196},"ACTIVE_NOT_RECRUITING",[65],"2022-12-21",25,[119],[60],{"trials":198,"activeCount":74},[],{"trials":200,"activeCount":74},[],{"intervention":44,"totalTrials":87,"cells":202},{"EARLY_PHASE1":203,"PHASE1":205,"PHASE2":207,"PHASE3":217,"PHASE4":219,"NA":221},{"trials":204,"activeCount":74},[],{"trials":206,"activeCount":74},[],{"trials":208,"activeCount":87,"soonestReadout":43},[209],{"nctId":41,"briefTitle":42,"status":80,"phases":210,"primaryCompletion":43,"completion":43,"start":211,"enrollment":212,"conditions":213,"interventions":215},[63,64],"2022-06-23",30,[214],"Bowel Preparation",[44,216],"MIRALAX",{"trials":218,"activeCount":74},[],{"trials":220,"activeCount":74},[],{"trials":222,"activeCount":74},[],{"intervention":216,"totalTrials":87,"cells":224},{"EARLY_PHASE1":225,"PHASE1":227,"PHASE2":229,"PHASE3":235,"PHASE4":237,"NA":239},{"trials":226,"activeCount":74},[],{"trials":228,"activeCount":74},[],{"trials":230,"activeCount":87,"soonestReadout":43},[231],{"nctId":41,"briefTitle":42,"status":80,"phases":232,"primaryCompletion":43,"completion":43,"start":211,"enrollment":212,"conditions":233,"interventions":234},[63,64],[214],[44,216],{"trials":236,"activeCount":74},[],{"trials":238,"activeCount":74},[],{"trials":240,"activeCount":74},[],{"intervention":39,"totalTrials":108,"cells":242},{"EARLY_PHASE1":243,"PHASE1":245,"PHASE2":247,"PHASE3":249,"PHASE4":261,"NA":263},{"trials":244,"activeCount":74},[],{"trials":246,"activeCount":74},[],{"trials":248,"activeCount":74},[],{"trials":250,"activeCount":74},[251],{"nctId":252,"briefTitle":253,"status":254,"phases":255,"primaryCompletion":256,"completion":256,"start":257,"enrollment":258,"conditions":259,"interventions":260},"NCT05263388","A Trial to Compare the Ovarian Response of REKOVELLE and GONAL-F in Conventional Dosing in Women Undergoing Controlled Ovarian Stimulation","COMPLETED",[65],"2024-04-16","2022-07-15",302,[16],[39],{"trials":262,"activeCount":74},[],{"trials":264,"activeCount":87,"soonestReadout":38},[265],{"nctId":36,"briefTitle":37,"status":191,"phases":266,"primaryCompletion":38,"completion":267,"start":268,"enrollment":269,"conditions":270,"interventions":271},[],"2027-08-01","2024-08-27",1500,[16],[39],{"intervention":273,"totalTrials":33,"cells":274},"Tranexamic acid",{"EARLY_PHASE1":275,"PHASE1":277,"PHASE2":279,"PHASE3":281,"PHASE4":319,"NA":330},{"trials":276,"activeCount":74},[],{"trials":278,"activeCount":74},[],{"trials":280,"activeCount":74},[],{"trials":282,"activeCount":74},[283,293,303,311],{"nctId":284,"briefTitle":285,"status":254,"phases":286,"primaryCompletion":287,"completion":287,"start":288,"enrollment":289,"conditions":290,"interventions":292},"NCT01280981","A Study of Tranexamic Acid (XP12B) in Women With Heavy Menstrual Bleeding",[65],"2009-05","2007-04",288,[291],"Menorrhagia",[273],{"nctId":294,"briefTitle":295,"status":254,"phases":296,"primaryCompletion":297,"completion":297,"start":298,"enrollment":299,"conditions":300,"interventions":302},"NCT00401193","Efficacy and Safety of XP12B in Women With Menorrhagia",[65],"2008-05","2006-11",304,[291,301],"Heavy Menstrual Bleeding",[273,273],{"nctId":304,"briefTitle":305,"status":254,"phases":306,"primaryCompletion":287,"completion":287,"start":307,"enrollment":308,"conditions":309,"interventions":310},"NCT00113568","Safety Study of XP12B in Women With Menorrhagia",[65],"2005-06",784,[291,301],[273],{"nctId":312,"briefTitle":313,"status":254,"phases":314,"primaryCompletion":297,"completion":297,"start":315,"enrollment":316,"conditions":317,"interventions":318},"NCT00386308","Efficacy and Safety Study of XP12B in Women With Menorrhagia",[65],"2006-10",196,[291,301],[273],{"trials":320,"activeCount":74},[321],{"nctId":322,"briefTitle":323,"status":254,"phases":324,"primaryCompletion":325,"completion":325,"start":326,"enrollment":83,"conditions":327,"interventions":328},"NCT01190150","Lysteda Pediatric Research Equity Act (PREA) Pharmacokinetic Study in Adolescent Females With Heavy Menstrual Bleeding",[66],"2011-04","2010-08",[291],[329],"tranexamic acid",{"trials":331,"activeCount":74},[],{"intervention":333,"totalTrials":33,"cells":334},"Follitropin Alfa",{"EARLY_PHASE1":335,"PHASE1":337,"PHASE2":339,"PHASE3":341,"PHASE4":384,"NA":397},{"trials":336,"activeCount":74},[],{"trials":338,"activeCount":74},[],{"trials":340,"activeCount":74},[],{"trials":342,"activeCount":74},[343,354,367,375],{"nctId":344,"briefTitle":345,"status":254,"phases":346,"primaryCompletion":347,"completion":348,"start":349,"enrollment":350,"conditions":351,"interventions":352},"NCT01956123","Evidence-based Stimulation Trial With Human rFSH in Europe and Rest of World 2",[65],"2015-05","2017-01-03","2014-03-26",513,[16],[353,333],"Follitropin Delta",{"nctId":355,"briefTitle":356,"status":254,"phases":357,"primaryCompletion":358,"completion":359,"start":360,"enrollment":361,"conditions":362,"interventions":364},"NCT03296527","Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in Pan-Asian Women",[65],"2020-01-03","2020-07-26","2017-12-01",1011,[363],"Controlled Ovarian Simulation",[365,366],"Follitropin alfa","Follitropin delta",{"nctId":368,"briefTitle":369,"status":254,"phases":370,"primaryCompletion":347,"completion":348,"start":371,"enrollment":372,"conditions":373,"interventions":374},"NCT01956110","Evidence-based Stimulation Trial With Human rFSH in Europe and Rest of World 1",[65],"2013-10",1329,[16],[353,333],{"nctId":376,"briefTitle":377,"status":254,"phases":378,"primaryCompletion":379,"completion":379,"start":380,"enrollment":381,"conditions":382,"interventions":383},"NCT04773353","Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in Indian Women",[65],"2023-12-12","2021-12-03",220,[16],[353,333],{"trials":385,"activeCount":74},[386],{"nctId":387,"briefTitle":388,"status":254,"phases":389,"primaryCompletion":390,"completion":391,"start":392,"enrollment":393,"conditions":394,"interventions":395},"NCT00257556","A Study of the Efficacy and Safety of Highly Purified Menotrophin Versus Recombinant Follitropin Alfa",[66],"2008-07","2009-04","2005-10",80,[16],[396,365],"Menotrophin",{"trials":398,"activeCount":74},[],{"intervention":400,"totalTrials":70,"cells":401},"Follitropin beta",{"EARLY_PHASE1":402,"PHASE1":404,"PHASE2":406,"PHASE3":420,"PHASE4":432,"NA":461},{"trials":403,"activeCount":74},[],{"trials":405,"activeCount":74},[],{"trials":407,"activeCount":74},[408],{"nctId":409,"briefTitle":410,"status":254,"phases":411,"primaryCompletion":412,"completion":413,"start":414,"enrollment":415,"conditions":416,"interventions":417},"NCT02309671","A Dose-response Trial Using FE 999049 in Japanese Women Undergoing in Vitro Fertilisation (IVF) \u002F Intracytoplasmic Sperm Injection (ICSI) Treatment",[64],"2015-11","2016-09","2014-12",159,[16],[418,419],"FE 999049","follitropin beta",{"trials":421,"activeCount":74},[422],{"nctId":423,"briefTitle":424,"status":254,"phases":425,"primaryCompletion":426,"completion":427,"start":428,"enrollment":429,"conditions":430,"interventions":431},"NCT03228680","Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in Japanese Women",[65],"2019-06-10","2019-07-08","2017-07-29",373,[16],[366,400],{"trials":433,"activeCount":74},[434,448],{"nctId":435,"briefTitle":436,"status":254,"phases":437,"primaryCompletion":438,"completion":439,"start":440,"enrollment":441,"conditions":442,"interventions":443},"NCT00802360","MENOPUR® Versus FOLLISTIM®",[66],"2009-11","2010-01","2008-12",173,[16],[444,445,419,446,447],"Menotropin","Progestrone vaginal insert","Progesterone in oil","Ganirelix",{"nctId":449,"briefTitle":450,"status":254,"phases":451,"primaryCompletion":452,"completion":453,"start":454,"enrollment":455,"conditions":456,"interventions":458},"NCT00805935","Menopur® Versus Follistim® in Polycystic Ovarian Syndrome (PCOS)",[66],"2010-07","2010-09","2009-01",110,[457,16],"Polycystic Ovarian Syndrome",[444,459,400,446,460],"Progesterone vaginal insert","leuprolide acetate",{"trials":462,"activeCount":74},[],{"intervention":464,"totalTrials":465,"cells":466},"bisacodyl",3,{"EARLY_PHASE1":467,"PHASE1":469,"PHASE2":471,"PHASE3":473,"PHASE4":493,"NA":507},{"trials":468,"activeCount":74},[],{"trials":470,"activeCount":74},[],{"trials":472,"activeCount":74},[],{"trials":474,"activeCount":74},[475,486],{"nctId":476,"briefTitle":477,"status":254,"phases":478,"primaryCompletion":479,"completion":479,"start":480,"enrollment":481,"conditions":482,"interventions":483},"NCT01073930","Investigation of PicoPrep Versus HalfLytely for Bowel Preparation for Colonoscopy - Split Dose PicoPrep",[65],"2010-10","2010-05",608,[214],[484,485,464],"PicoPrep","HalfLytely",{"nctId":487,"briefTitle":488,"status":254,"phases":489,"primaryCompletion":479,"completion":479,"start":480,"enrollment":490,"conditions":491,"interventions":492},"NCT01073943","Investigation of PicoPrep Versus HalfLytely for Bowel Preparation for Colonoscopy - Day Before PicoPrep",[65],603,[214],[484,485,464],{"trials":494,"activeCount":74},[495],{"nctId":496,"briefTitle":497,"status":254,"phases":498,"primaryCompletion":499,"completion":499,"start":500,"enrollment":501,"conditions":502,"interventions":503},"NCT02386449","A Study Comparing Picoprep With Mannitol and Bisacodyl for Colon Cleansing in Preparation for Colonoscopy",[66],"2015-12","2015-02",184,[214],[504,505,506],"sodium picosulfate, magnesium oxide and citric acid","mannitol","Bisacodyl",{"trials":508,"activeCount":74},[],{"intervention":510,"totalTrials":465,"cells":511},"Dinoprostone",{"EARLY_PHASE1":512,"PHASE1":514,"PHASE2":516,"PHASE3":518,"PHASE4":538,"NA":553},{"trials":513,"activeCount":74},[],{"trials":515,"activeCount":74},[],{"trials":517,"activeCount":74},[],{"trials":519,"activeCount":74},[520,529],{"nctId":521,"briefTitle":522,"status":254,"phases":523,"primaryCompletion":524,"completion":524,"start":525,"enrollment":526,"conditions":527,"interventions":528},"NCT03067597","An Open-label Trial Investigating the Efficacy and Safety of a Vaginal Insert in Pregnant Women at Term",[65],"2018-02-24","2017-02-22",68,[25],[510],{"nctId":530,"briefTitle":531,"status":254,"phases":532,"primaryCompletion":533,"completion":533,"start":534,"enrollment":535,"conditions":536,"interventions":537},"NCT03067727","A Randomised Trial Investigating the Efficacy and Safety of a Vaginal Insert in Pregnant Women at Term",[65],"2018-08-30","2017-04-03",114,[25],[510],{"trials":539,"activeCount":74},[540],{"nctId":541,"briefTitle":542,"status":543,"phases":544,"primaryCompletion":545,"completion":545,"start":546,"enrollment":547,"conditions":548,"interventions":551},"NCT01190163","Open Label Comparative Trial of Dinoprostone Plus or Minus Oxytocin Versus Oxytocin Alone in Cervical Ripening for Labor Induction","TERMINATED",[66],"2012-01","2010-06",170,[549,550],"Vaginal Delivery","Cesarean Section",[510,552],"Oxytocin",{"trials":554,"activeCount":74},[],{"intervention":556,"totalTrials":108,"cells":557},"recombinant FSH",{"EARLY_PHASE1":558,"PHASE1":560,"PHASE2":562,"PHASE3":564,"PHASE4":577,"NA":590},{"trials":559,"activeCount":74},[],{"trials":561,"activeCount":74},[],{"trials":563,"activeCount":74},[],{"trials":565,"activeCount":74},[566],{"nctId":567,"briefTitle":568,"status":254,"phases":569,"primaryCompletion":452,"completion":570,"start":571,"enrollment":572,"conditions":573,"interventions":574},"NCT00884221","MENOPUR in Gonadotrophin-releasing Hormone (GnRH) Antagonist Cycles With Single Embryo Transfer",[65],"2011-01","2009-07",749,[16],[575,576],"Highly purified menotrophin","Recombinant FSH",{"trials":578,"activeCount":74},[579],{"nctId":580,"briefTitle":581,"status":254,"phases":582,"primaryCompletion":583,"completion":584,"start":585,"enrollment":586,"conditions":587,"interventions":588},"NCT02554279","MENOPUR® in a Gonadotropin-Releasing Hormone (GnRH) Antagonist Cycle With Single-Blastocyst Transfer in a High Responder Subject Population",[66],"2017-01-26","2017-02-02","2015-08-31",620,[16],[589,556],"menotropin",{"trials":591,"activeCount":74},[],{"intervention":446,"totalTrials":108,"cells":593},{"EARLY_PHASE1":594,"PHASE1":596,"PHASE2":598,"PHASE3":600,"PHASE4":602,"NA":612},{"trials":595,"activeCount":74},[],{"trials":597,"activeCount":74},[],{"trials":599,"activeCount":74},[],{"trials":601,"activeCount":74},[],{"trials":603,"activeCount":74},[604,608],{"nctId":435,"briefTitle":436,"status":254,"phases":605,"primaryCompletion":438,"completion":439,"start":440,"enrollment":441,"conditions":606,"interventions":607},[66],[16],[444,445,419,446,447],{"nctId":449,"briefTitle":450,"status":254,"phases":609,"primaryCompletion":452,"completion":453,"start":454,"enrollment":455,"conditions":610,"interventions":611},[66],[457,16],[444,459,400,446,460],{"trials":613,"activeCount":74},[],{"intervention":615,"totalTrials":87,"cells":616},"Primary nocturnal enuresis",{"EARLY_PHASE1":617,"PHASE1":619,"PHASE2":621,"PHASE3":623,"PHASE4":625,"NA":637},{"trials":618,"activeCount":74},[],{"trials":620,"activeCount":74},[],{"trials":622,"activeCount":74},[],{"trials":624,"activeCount":74},[],{"trials":626,"activeCount":74},[627],{"nctId":628,"briefTitle":629,"status":254,"phases":630,"primaryCompletion":631,"completion":298,"start":632,"enrollment":633,"conditions":634,"interventions":636},"NCT00245479","A Study of Oral Desmopressin in Previously Untreated Children Aged 5 to 15 Years With Primary Nocturnal Enuresis",[66],"2005-09","2002-04",802,[635],"Nocturnal Enuresis",[615],{"trials":638,"activeCount":74},[],{"intervention":640,"totalTrials":87,"cells":641},"Bravelle",{"EARLY_PHASE1":642,"PHASE1":644,"PHASE2":646,"PHASE3":648,"PHASE4":650,"NA":661},{"trials":643,"activeCount":74},[],{"trials":645,"activeCount":74},[],{"trials":647,"activeCount":74},[],{"trials":649,"activeCount":74},[],{"trials":651,"activeCount":74},[652],{"nctId":653,"briefTitle":654,"status":254,"phases":655,"primaryCompletion":545,"completion":545,"start":656,"enrollment":657,"conditions":658,"interventions":659},"NCT01417195","Menopur Mixed Protocol",[66],"2011-07",122,[16],[640,660],"Menopur",{"trials":662,"activeCount":74},[],{"intervention":660,"totalTrials":87,"cells":664},{"EARLY_PHASE1":665,"PHASE1":667,"PHASE2":669,"PHASE3":671,"PHASE4":673,"NA":679},{"trials":666,"activeCount":74},[],{"trials":668,"activeCount":74},[],{"trials":670,"activeCount":74},[],{"trials":672,"activeCount":74},[],{"trials":674,"activeCount":74},[675],{"nctId":653,"briefTitle":654,"status":254,"phases":676,"primaryCompletion":545,"completion":545,"start":656,"enrollment":657,"conditions":677,"interventions":678},[66],[16],[640,660],{"trials":680,"activeCount":74},[],{"intervention":445,"totalTrials":87,"cells":682},{"EARLY_PHASE1":683,"PHASE1":685,"PHASE2":687,"PHASE3":689,"PHASE4":691,"NA":697},{"trials":684,"activeCount":74},[],{"trials":686,"activeCount":74},[],{"trials":688,"activeCount":74},[],{"trials":690,"activeCount":74},[],{"trials":692,"activeCount":74},[693],{"nctId":435,"briefTitle":436,"status":254,"phases":694,"primaryCompletion":438,"completion":439,"start":440,"enrollment":441,"conditions":695,"interventions":696},[66],[16],[444,445,419,446,447],{"trials":698,"activeCount":74},[],{"intervention":447,"totalTrials":87,"cells":700},{"EARLY_PHASE1":701,"PHASE1":703,"PHASE2":705,"PHASE3":707,"PHASE4":709,"NA":715},{"trials":702,"activeCount":74},[],{"trials":704,"activeCount":74},[],{"trials":706,"activeCount":74},[],{"trials":708,"activeCount":74},[],{"trials":710,"activeCount":74},[711],{"nctId":435,"briefTitle":436,"status":254,"phases":712,"primaryCompletion":438,"completion":439,"start":440,"enrollment":441,"conditions":713,"interventions":714},[66],[16],[444,445,419,446,447],{"trials":716,"activeCount":74},[],{"intervention":459,"totalTrials":87,"cells":718},{"EARLY_PHASE1":719,"PHASE1":721,"PHASE2":723,"PHASE3":725,"PHASE4":727,"NA":733},{"trials":720,"activeCount":74},[],{"trials":722,"activeCount":74},[],{"trials":724,"activeCount":74},[],{"trials":726,"activeCount":74},[],{"trials":728,"activeCount":74},[729],{"nctId":449,"briefTitle":450,"status":254,"phases":730,"primaryCompletion":452,"completion":453,"start":454,"enrollment":455,"conditions":731,"interventions":732},[66],[457,16],[444,459,400,446,460],{"trials":734,"activeCount":74},[],{"intervention":460,"totalTrials":87,"cells":736},{"EARLY_PHASE1":737,"PHASE1":739,"PHASE2":741,"PHASE3":743,"PHASE4":745,"NA":751},{"trials":738,"activeCount":74},[],{"trials":740,"activeCount":74},[],{"trials":742,"activeCount":74},[],{"trials":744,"activeCount":74},[],{"trials":746,"activeCount":74},[747],{"nctId":449,"briefTitle":450,"status":254,"phases":748,"primaryCompletion":452,"completion":453,"start":454,"enrollment":455,"conditions":749,"interventions":750},[66],[457,16],[444,459,400,446,460],{"trials":752,"activeCount":74},[],{"intervention":754,"totalTrials":87,"cells":755},"Follitrophin alpha",{"EARLY_PHASE1":756,"PHASE1":758,"PHASE2":760,"PHASE3":762,"PHASE4":764,"NA":778},{"trials":757,"activeCount":74},[],{"trials":759,"activeCount":74},[],{"trials":761,"activeCount":74},[],{"trials":763,"activeCount":74},[],{"trials":765,"activeCount":74},[766],{"nctId":767,"briefTitle":768,"status":254,"phases":769,"primaryCompletion":770,"completion":771,"start":479,"enrollment":772,"conditions":773,"interventions":774},"NCT01225835","Progesterone Serum Levels in Subfertile Female Patients Undergoing in Vitro Fertilisation (IVF)",[66],"2013-01","2013-06",124,[16],[396,754,775,776,777],"Cetrorelix","Choriongonadotropin","Progesterone",{"trials":779,"activeCount":74},[],{"intervention":775,"totalTrials":87,"cells":781},{"EARLY_PHASE1":782,"PHASE1":784,"PHASE2":786,"PHASE3":788,"PHASE4":790,"NA":796},{"trials":783,"activeCount":74},[],{"trials":785,"activeCount":74},[],{"trials":787,"activeCount":74},[],{"trials":789,"activeCount":74},[],{"trials":791,"activeCount":74},[792],{"nctId":767,"briefTitle":768,"status":254,"phases":793,"primaryCompletion":770,"completion":771,"start":479,"enrollment":772,"conditions":794,"interventions":795},[66],[16],[396,754,775,776,777],{"trials":797,"activeCount":74},[],{"intervention":776,"totalTrials":87,"cells":799},{"EARLY_PHASE1":800,"PHASE1":802,"PHASE2":804,"PHASE3":806,"PHASE4":808,"NA":814},{"trials":801,"activeCount":74},[],{"trials":803,"activeCount":74},[],{"trials":805,"activeCount":74},[],{"trials":807,"activeCount":74},[],{"trials":809,"activeCount":74},[810],{"nctId":767,"briefTitle":768,"status":254,"phases":811,"primaryCompletion":770,"completion":771,"start":479,"enrollment":772,"conditions":812,"interventions":813},[66],[16],[396,754,775,776,777],{"trials":815,"activeCount":74},[],{"intervention":777,"totalTrials":87,"cells":817},{"EARLY_PHASE1":818,"PHASE1":820,"PHASE2":822,"PHASE3":824,"PHASE4":826,"NA":832},{"trials":819,"activeCount":74},[],{"trials":821,"activeCount":74},[],{"trials":823,"activeCount":74},[],{"trials":825,"activeCount":74},[],{"trials":827,"activeCount":74},[828],{"nctId":767,"briefTitle":768,"status":254,"phases":829,"primaryCompletion":770,"completion":771,"start":479,"enrollment":772,"conditions":830,"interventions":831},[66],[16],[396,754,775,776,777],{"trials":833,"activeCount":74},[],{"intervention":835,"totalTrials":87,"cells":836},"MINIRIN Oral Lyophilisate",{"EARLY_PHASE1":837,"PHASE1":839,"PHASE2":841,"PHASE3":843,"PHASE4":845,"NA":858},{"trials":838,"activeCount":74},[],{"trials":840,"activeCount":74},[],{"trials":842,"activeCount":74},[],{"trials":844,"activeCount":74},[],{"trials":846,"activeCount":74},[847],{"nctId":848,"briefTitle":849,"status":254,"phases":850,"primaryCompletion":851,"completion":631,"start":852,"enrollment":853,"conditions":854,"interventions":856},"NCT00209261","A 6-week Open Label Cross-over Study With 2 Different Daily Doses of Minirin® Oral Lyophilisate in Children and Adolescents With Primary Nocturnal Enuresis (PNE)",[66],"2005-08","2004-12",221,[855],"Primary Nocturnal Enuresis",[835,857],"Minirin",{"trials":859,"activeCount":74},[],{"intervention":857,"totalTrials":87,"cells":861},{"EARLY_PHASE1":862,"PHASE1":864,"PHASE2":866,"PHASE3":868,"PHASE4":870,"NA":876},{"trials":863,"activeCount":74},[],{"trials":865,"activeCount":74},[],{"trials":867,"activeCount":74},[],{"trials":869,"activeCount":74},[],{"trials":871,"activeCount":74},[872],{"nctId":848,"briefTitle":849,"status":254,"phases":873,"primaryCompletion":851,"completion":631,"start":852,"enrollment":853,"conditions":874,"interventions":875},[66],[855],[835,857],{"trials":877,"activeCount":74},[],{"intervention":30,"totalTrials":87,"cells":879},{"EARLY_PHASE1":880,"PHASE1":882,"PHASE2":884,"PHASE3":886,"PHASE4":888,"NA":898},{"trials":881,"activeCount":74},[],{"trials":883,"activeCount":74},[],{"trials":885,"activeCount":74},[],{"trials":887,"activeCount":74},[],{"trials":889,"activeCount":74},[890],{"nctId":891,"briefTitle":892,"status":254,"phases":893,"primaryCompletion":894,"completion":894,"start":392,"enrollment":895,"conditions":896,"interventions":897},"NCT00225810","A Study Comparing the Acceptability of Pentasa® Sachets Versus Pentasa® Tablets in Children With Crohn´s Disease",[66],"2006-02",50,[30],[30],{"trials":899,"activeCount":74},[],{"intervention":552,"totalTrials":87,"cells":901},{"EARLY_PHASE1":902,"PHASE1":904,"PHASE2":906,"PHASE3":908,"PHASE4":910,"NA":916},{"trials":903,"activeCount":74},[],{"trials":905,"activeCount":74},[],{"trials":907,"activeCount":74},[],{"trials":909,"activeCount":74},[],{"trials":911,"activeCount":74},[912],{"nctId":541,"briefTitle":542,"status":543,"phases":913,"primaryCompletion":545,"completion":545,"start":546,"enrollment":547,"conditions":914,"interventions":915},[66],[549,550],[510,552],{"trials":917,"activeCount":74},[],{"intervention":505,"totalTrials":87,"cells":919},{"EARLY_PHASE1":920,"PHASE1":922,"PHASE2":924,"PHASE3":926,"PHASE4":928,"NA":934},{"trials":921,"activeCount":74},[],{"trials":923,"activeCount":74},[],{"trials":925,"activeCount":74},[],{"trials":927,"activeCount":74},[],{"trials":929,"activeCount":74},[930],{"nctId":496,"briefTitle":497,"status":254,"phases":931,"primaryCompletion":499,"completion":499,"start":500,"enrollment":501,"conditions":932,"interventions":933},[66],[214],[504,505,506],{"trials":935,"activeCount":74},[],{"intervention":937,"totalTrials":33,"cells":938},"Testosterone gel",{"EARLY_PHASE1":939,"PHASE1":941,"PHASE2":943,"PHASE3":963,"PHASE4":993,"NA":995},{"trials":940,"activeCount":74},[],{"trials":942,"activeCount":74},[],{"trials":944,"activeCount":74},[945,953],{"nctId":946,"briefTitle":947,"status":254,"phases":948,"primaryCompletion":656,"completion":656,"start":949,"enrollment":83,"conditions":950,"interventions":952},"NCT01370369","Efficacy, Pharmacokinetics and Safety of Testosterone",[64],"2011-05",[951],"Testicular Hypogonadism",[937],{"nctId":954,"briefTitle":955,"status":254,"phases":956,"primaryCompletion":957,"completion":957,"start":958,"enrollment":83,"conditions":959,"interventions":961},"NCT01464879","A Clinical Study to Evaluate the Pharmacokinetics of Testosterone Gel Using an Applicator",[64],"2012-05","2011-12",[960],"Hypogonadal Males",[962],"Testosterone Gel",{"trials":964,"activeCount":74},[965,975,983],{"nctId":966,"briefTitle":967,"status":254,"phases":968,"primaryCompletion":347,"completion":969,"start":970,"enrollment":971,"conditions":972,"interventions":974},"NCT02149264","A Clinical Trial to Evaluate the Efficacy and Safety of Testosterone Gel in Adult Hypogonadal Males",[65],"2015-06","2014-07",160,[973],"Adult Male Hypogonadism",[937],{"nctId":976,"briefTitle":977,"status":254,"phases":978,"primaryCompletion":371,"completion":371,"start":979,"enrollment":980,"conditions":981,"interventions":982},"NCT01703741","A Multicenter Extension Trial to Evaluate the Safety of Testosterone Gel",[65],"2012-12",145,[973],[962],{"nctId":984,"briefTitle":985,"status":254,"phases":986,"primaryCompletion":987,"completion":988,"start":989,"enrollment":990,"conditions":991,"interventions":992},"NCT01665599","A Clinical Trial to Evaluate the Efficacy and Safety of Testosterone Gel",[65],"2013-04","2013-05","2012-07",180,[973],[937],{"trials":994,"activeCount":74},[],{"trials":996,"activeCount":74},[],{"intervention":998,"totalTrials":70,"cells":999},"Goserelin",{"EARLY_PHASE1":1000,"PHASE1":1002,"PHASE2":1004,"PHASE3":1006,"PHASE4":1041,"NA":1043},{"trials":1001,"activeCount":74},[],{"trials":1003,"activeCount":74},[],{"trials":1005,"activeCount":74},[],{"trials":1007,"activeCount":74},[1008,1018,1027,1034],{"nctId":1009,"briefTitle":1010,"status":254,"phases":1011,"primaryCompletion":1012,"completion":1012,"start":391,"enrollment":1013,"conditions":1014,"interventions":1015},"NCT00833248","Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer",[65],"2011-09",246,[14],[1016,998,1017],"Degarelix","Bicalutamide",{"nctId":1019,"briefTitle":1020,"status":254,"phases":1021,"primaryCompletion":1022,"completion":1022,"start":1023,"enrollment":1024,"conditions":1025,"interventions":1026},"NCT00884273","Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients",[65],"2011-03","2009-08",182,[14],[1016,998,1017],{"nctId":1028,"briefTitle":1029,"status":543,"phases":1030,"primaryCompletion":546,"completion":452,"start":391,"enrollment":1031,"conditions":1032,"interventions":1033},"NCT00831233","Symptomatic Study Investigating Degarelix in Patients Suffering From Prostate Cancer",[65],42,[14],[1016,998,1017],{"nctId":1035,"briefTitle":1036,"status":254,"phases":1037,"primaryCompletion":347,"completion":347,"start":770,"enrollment":1038,"conditions":1039,"interventions":1040},"NCT01744366","One Month Degarelix\u002FComparator Treatment for Prostate Cancer in Chinese Population",[65],285,[14],[1016,998],{"trials":1042,"activeCount":74},[],{"trials":1044,"activeCount":74},[],{"intervention":418,"totalTrials":70,"cells":1046},{"EARLY_PHASE1":1047,"PHASE1":1049,"PHASE2":1051,"PHASE3":1077,"PHASE4":1089,"NA":1091},{"trials":1048,"activeCount":74},[],{"trials":1050,"activeCount":74},[],{"trials":1052,"activeCount":74},[1053,1063,1073],{"nctId":1054,"briefTitle":1055,"status":254,"phases":1056,"primaryCompletion":1057,"completion":1058,"start":1012,"enrollment":1059,"conditions":1060,"interventions":1061},"NCT01426386","A Dose-response Trial Using rFSH FE 999049 in Women Undergoing IVF\u002FICSI Treatment",[64],"2012-04","2013-03",265,[16],[418,1062],"Gonal - F",{"nctId":1064,"briefTitle":1065,"status":543,"phases":1066,"primaryCompletion":1067,"completion":1068,"start":1069,"enrollment":70,"conditions":1070,"interventions":1072},"NCT05403476","A Trial to Compare Efficacy and Safety of Follitropin Delta Versus Placebo (Inactive Treatment) in the Treatment of Men With Idiopathic Infertility (Unexplained Reduction of Semen Quality) (ADAM)",[64],"2024-10-05","2024-10-23","2022-08-16",[1071],"Male Idiopathic Infertility",[418],{"nctId":409,"briefTitle":410,"status":254,"phases":1074,"primaryCompletion":412,"completion":413,"start":414,"enrollment":415,"conditions":1075,"interventions":1076},[64],[16],[418,419],{"trials":1078,"activeCount":74},[1079],{"nctId":1080,"briefTitle":1081,"status":254,"phases":1082,"primaryCompletion":1083,"completion":1083,"start":1084,"enrollment":1085,"conditions":1086,"interventions":1087},"NCT06173869","A Randomised Trial Comparing the Ovarian Response of a Starting Dose of Either 10 μg or 15 μg Follitropin Delta (FE 999049) to a Starting Dose of Either 150 IU or 225 IU Follitropin Alfa (GONAL-F) in Conventional Regimens in China",[65],"2025-05-31","2024-03-29",301,[28],[418,1088],"GONAL-F",{"trials":1090,"activeCount":74},[],{"trials":1092,"activeCount":74},[],{"intervention":484,"totalTrials":70,"cells":1094},{"EARLY_PHASE1":1095,"PHASE1":1097,"PHASE2":1099,"PHASE3":1101,"PHASE4":1130,"NA":1132},{"trials":1096,"activeCount":74},[],{"trials":1098,"activeCount":74},[],{"trials":1100,"activeCount":74},[],{"trials":1102,"activeCount":74},[1103,1107,1117,1121],{"nctId":476,"briefTitle":477,"status":254,"phases":1104,"primaryCompletion":479,"completion":479,"start":480,"enrollment":481,"conditions":1105,"interventions":1106},[65],[214],[484,485,464],{"nctId":1108,"briefTitle":1109,"status":254,"phases":1110,"primaryCompletion":949,"completion":656,"start":570,"enrollment":1111,"conditions":1112,"interventions":1114},"NCT01356407","Investigation of PICOPREP and PEG-ELS for Bowel Preparation for Colonoscopy",[65],300,[1113],"Colonoscopy",[1115,1116],"PICOPREP","PEG-ELS",{"nctId":487,"briefTitle":488,"status":254,"phases":1118,"primaryCompletion":479,"completion":479,"start":480,"enrollment":490,"conditions":1119,"interventions":1120},[65],[214],[484,485,464],{"nctId":1122,"briefTitle":1123,"status":254,"phases":1124,"primaryCompletion":969,"completion":969,"start":1125,"enrollment":1126,"conditions":1127,"interventions":1129},"NCT02239692","A Trial Comparing the PICOPREP Tailored Dosing Schedule to the PICOPREP Day-before Dosing Schedule for Colon Cleansing in Preparation for Colonoscopy",[65],"2014-11",204,[1128],"Bowel Cleansing",[1115],{"trials":1131,"activeCount":74},[],{"trials":1133,"activeCount":74},[],{"intervention":1017,"totalTrials":465,"cells":1135},{"EARLY_PHASE1":1136,"PHASE1":1138,"PHASE2":1140,"PHASE3":1142,"PHASE4":1156,"NA":1158},{"trials":1137,"activeCount":74},[],{"trials":1139,"activeCount":74},[],{"trials":1141,"activeCount":74},[],{"trials":1143,"activeCount":74},[1144,1148,1152],{"nctId":1009,"briefTitle":1010,"status":254,"phases":1145,"primaryCompletion":1012,"completion":1012,"start":391,"enrollment":1013,"conditions":1146,"interventions":1147},[65],[14],[1016,998,1017],{"nctId":1019,"briefTitle":1020,"status":254,"phases":1149,"primaryCompletion":1022,"completion":1022,"start":1023,"enrollment":1024,"conditions":1150,"interventions":1151},[65],[14],[1016,998,1017],{"nctId":1028,"briefTitle":1029,"status":543,"phases":1153,"primaryCompletion":546,"completion":452,"start":391,"enrollment":1031,"conditions":1154,"interventions":1155},[65],[14],[1016,998,1017],{"trials":1157,"activeCount":74},[],{"trials":1159,"activeCount":74},[],{"intervention":1161,"totalTrials":465,"cells":1162},"MVI 200",{"EARLY_PHASE1":1163,"PHASE1":1165,"PHASE2":1167,"PHASE3":1187,"PHASE4":1199,"NA":1201},{"trials":1164,"activeCount":74},[],{"trials":1166,"activeCount":74},[],{"trials":1168,"activeCount":74},[1169,1177],{"nctId":1170,"briefTitle":1171,"status":254,"phases":1172,"primaryCompletion":656,"completion":656,"start":949,"enrollment":1173,"conditions":1174,"interventions":1176},"NCT01283022","Pharmacokinetic (PK) Study of the 200 Microgram (mcg) Misoprostol Vaginal Insert (MVI 200) in Women at Term Gestation (The MVI-PK Study)",[64],24,[25,1175],"Induction of Labor",[1161],{"nctId":1178,"briefTitle":1179,"status":254,"phases":1180,"primaryCompletion":1181,"completion":1181,"start":391,"enrollment":1182,"conditions":1183,"interventions":1184},"NCT00828711","Misoprostol Vaginal Insert (MVI) 100, 150, 200 mcg for Cervical Ripening and Induction of Labor",[64],"2009-12",374,[25,1175],[1185,1186,1161],"MVI 100","MVI 150",{"trials":1188,"activeCount":74},[1189],{"nctId":1190,"briefTitle":1191,"status":254,"phases":1192,"primaryCompletion":1193,"completion":1193,"start":453,"enrollment":1194,"conditions":1195,"interventions":1197},"NCT01127581","Efficacy & Safety Study Comparing Misoprostol Vaginal Insert (MVI) Versus Dinoprostone Vaginal Insert (DVI) for Reducing Time to Vaginal Delivery",[65],"2012-03",1358,[1196,25,1175],"Reducing Time to Vaginal Delivery",[1161,1198],"Dinoprostone Vaginal Insert",{"trials":1200,"activeCount":74},[],{"trials":1202,"activeCount":74},[],{"intervention":1204,"totalTrials":108,"cells":1205},"clomiphene citrate",{"EARLY_PHASE1":1206,"PHASE1":1208,"PHASE2":1210,"PHASE3":1221,"PHASE4":1235,"NA":1237},{"trials":1207,"activeCount":74},[],{"trials":1209,"activeCount":74},[],{"trials":1211,"activeCount":74},[1212],{"nctId":1213,"briefTitle":1214,"status":254,"phases":1215,"primaryCompletion":1181,"completion":439,"start":1216,"enrollment":1217,"conditions":1218,"interventions":1219},"NCT00796289","Study to Assess the Efficacy and Safety of Three Dosage Strengths of Pulsatile GnRH Delivered From a Iontophoretic Patch Compared to Oral Treatment With Clomiphene or Placebo in Infertile Females",[64],"2009-02",350,[16],[1220,1220,1220,1204],"GnRH iontophoretic transdermal Lutrepatch",{"trials":1222,"activeCount":74},[1223],{"nctId":1224,"briefTitle":1225,"status":254,"phases":1226,"primaryCompletion":1227,"completion":1227,"start":1228,"enrollment":1229,"conditions":1230,"interventions":1232},"NCT00296465","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Dosage Strengths of Pulsatile GnRH",[64,65],"2005-11","2005-02",132,[1231],"InFertility",[1233,1234],"Pulsatile gonadotropin-releasing hormone","Clomiphene Citrate",{"trials":1236,"activeCount":74},[],{"trials":1238,"activeCount":74},[],{"intervention":1240,"totalTrials":108,"cells":1241},"Leuprolide",{"EARLY_PHASE1":1242,"PHASE1":1244,"PHASE2":1246,"PHASE3":1248,"PHASE4":1267,"NA":1269},{"trials":1243,"activeCount":74},[],{"trials":1245,"activeCount":74},[],{"trials":1247,"activeCount":74},[],{"trials":1249,"activeCount":74},[1250,1258],{"nctId":1251,"briefTitle":1252,"status":254,"phases":1253,"primaryCompletion":1254,"completion":1254,"start":287,"enrollment":1255,"conditions":1256,"interventions":1257},"NCT00928434","A Study of Degarelix in Patients With Prostate Cancer",[65],"2012-08",409,[14],[1016,1016,1240],{"nctId":1259,"briefTitle":1260,"status":543,"phases":1261,"primaryCompletion":1262,"completion":1262,"start":1263,"enrollment":1264,"conditions":1265,"interventions":1266},"NCT02663908","A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease",[65],"2021-03-29","2016-04-19",545,[14],[1016,1240],{"trials":1268,"activeCount":74},[],{"trials":1270,"activeCount":74},[],{"intervention":1272,"totalTrials":108,"cells":1273},"Glycerine",{"EARLY_PHASE1":1274,"PHASE1":1276,"PHASE2":1278,"PHASE3":1290,"PHASE4":1299,"NA":1301},{"trials":1275,"activeCount":74},[],{"trials":1277,"activeCount":74},[],{"trials":1279,"activeCount":74},[1280],{"nctId":1281,"briefTitle":1282,"status":254,"phases":1283,"primaryCompletion":452,"completion":452,"start":1284,"enrollment":1285,"conditions":1286,"interventions":1288},"NCT01335386","Investigation of KLYX in Patients With Constipation",[64],"2010-04",60,[1287],"Constipation",[1289,1272],"KLYX",{"trials":1291,"activeCount":74},[1292],{"nctId":1293,"briefTitle":1294,"status":254,"phases":1295,"primaryCompletion":1193,"completion":957,"start":1012,"enrollment":1111,"conditions":1296,"interventions":1297},"NCT01474499","A Trial of Docusate Sodium and Sorbitol Rectal Solution for the in Patients With Constipation",[65],[1287],[1272,1298],"Docusate sodium and sorbitol rectal solution",{"trials":1300,"activeCount":74},[],{"trials":1302,"activeCount":74},[],{"intervention":1304,"totalTrials":108,"cells":1305},"Mesalamine",{"EARLY_PHASE1":1306,"PHASE1":1308,"PHASE2":1310,"PHASE3":1312,"PHASE4":1333,"NA":1335},{"trials":1307,"activeCount":74},[],{"trials":1309,"activeCount":74},[],{"trials":1311,"activeCount":74},[],{"trials":1313,"activeCount":74},[1314,1324],{"nctId":1315,"briefTitle":1316,"status":254,"phases":1317,"primaryCompletion":1318,"completion":1319,"start":1320,"enrollment":1321,"conditions":1322,"interventions":1323},"NCT02522767","Mesalamine 4 g Sachet for the Induction of Remission in Active, Mild to Moderate Ulcerative Colitis (UC)",[65],"2018-02-06","2018-04-03","2015-10",228,[22],[1304],{"nctId":1325,"briefTitle":1326,"status":254,"phases":1327,"primaryCompletion":1328,"completion":1328,"start":1329,"enrollment":1330,"conditions":1331,"interventions":1332},"NCT02522780","Mesalamine 2 g Sachet for the Maintenance of Clinical and Endoscopic Remission in Ulcerative Colitis (UC)",[65],"2018-09-19","2016-02-01",276,[22],[1304],{"trials":1334,"activeCount":74},[],{"trials":1336,"activeCount":74},[],{"intervention":485,"totalTrials":108,"cells":1338},{"EARLY_PHASE1":1339,"PHASE1":1341,"PHASE2":1343,"PHASE3":1345,"PHASE4":1355,"NA":1357},{"trials":1340,"activeCount":74},[],{"trials":1342,"activeCount":74},[],{"trials":1344,"activeCount":74},[],{"trials":1346,"activeCount":74},[1347,1351],{"nctId":476,"briefTitle":477,"status":254,"phases":1348,"primaryCompletion":479,"completion":479,"start":480,"enrollment":481,"conditions":1349,"interventions":1350},[65],[214],[484,485,464],{"nctId":487,"briefTitle":488,"status":254,"phases":1352,"primaryCompletion":479,"completion":479,"start":480,"enrollment":490,"conditions":1353,"interventions":1354},[65],[214],[484,485,464],{"trials":1356,"activeCount":74},[],{"trials":1358,"activeCount":74},[],{"intervention":1360,"totalTrials":108,"cells":1361},"Goserelin acetate",{"EARLY_PHASE1":1362,"PHASE1":1364,"PHASE2":1366,"PHASE3":1368,"PHASE4":1384,"NA":1386},{"trials":1363,"activeCount":74},[],{"trials":1365,"activeCount":74},[],{"trials":1367,"activeCount":74},[],{"trials":1369,"activeCount":74},[1370,1376],{"nctId":1371,"briefTitle":1372,"status":543,"phases":1373,"primaryCompletion":958,"completion":545,"start":479,"enrollment":289,"conditions":1374,"interventions":1375},"NCT01242748","A Degarelix Trial in Patients With Prostate Cancer",[65],[14],[1016,1360],{"nctId":1377,"briefTitle":1378,"status":254,"phases":1379,"primaryCompletion":1022,"completion":1022,"start":1380,"enrollment":1381,"conditions":1382,"interventions":1383},"NCT00946920","A Trial of Degarelix in Patients With Prostate Cancer",[65],"2009-06",859,[14],[1016,1360],{"trials":1385,"activeCount":74},[],{"trials":1387,"activeCount":74},[],{"intervention":1389,"totalTrials":108,"cells":1390},"Misoprostol vaginal insert 50 mcg",{"EARLY_PHASE1":1391,"PHASE1":1393,"PHASE2":1395,"PHASE3":1410,"PHASE4":1423,"NA":1425},{"trials":1392,"activeCount":74},[],{"trials":1394,"activeCount":74},[],{"trials":1396,"activeCount":74},[1397],{"nctId":1398,"briefTitle":1399,"status":254,"phases":1400,"primaryCompletion":1401,"completion":1402,"start":1403,"enrollment":772,"conditions":1404,"interventions":1406},"NCT00346840","Safety and Efficacy Study of Misoprostol Vaginal Insert for Induction of Labour",[64],"2004-02","2004-03","2003-06",[1405,25],"Labor Induction",[1407,1389,1408,1409],"Misoprostol vaginal insert 25 mcg","Misoprostol vaginal insert 100 mcg","Misoprostol vaginal insert 200 mcg",{"trials":1411,"activeCount":74},[1412],{"nctId":1413,"briefTitle":1414,"status":254,"phases":1415,"primaryCompletion":1416,"completion":1416,"start":1417,"enrollment":1418,"conditions":1419,"interventions":1421},"NCT00308711","Safety\u002FEfficacy Study Comparing the Misoprostol Vaginal Insert to Cervidil for Cervical Ripening and Induction of Labor",[65],"2007-08","2006-04",1308,[25,1420],"Labor, Induced",[1408,1389,1422],"Dinoprostone vaginal insert",{"trials":1424,"activeCount":74},[],{"trials":1426,"activeCount":74},[],{"intervention":1408,"totalTrials":108,"cells":1428},{"EARLY_PHASE1":1429,"PHASE1":1431,"PHASE2":1433,"PHASE3":1439,"PHASE4":1445,"NA":1447},{"trials":1430,"activeCount":74},[],{"trials":1432,"activeCount":74},[],{"trials":1434,"activeCount":74},[1435],{"nctId":1398,"briefTitle":1399,"status":254,"phases":1436,"primaryCompletion":1401,"completion":1402,"start":1403,"enrollment":772,"conditions":1437,"interventions":1438},[64],[1405,25],[1407,1389,1408,1409],{"trials":1440,"activeCount":74},[1441],{"nctId":1413,"briefTitle":1414,"status":254,"phases":1442,"primaryCompletion":1416,"completion":1416,"start":1417,"enrollment":1418,"conditions":1443,"interventions":1444},[65],[25,1420],[1408,1389,1422],{"trials":1446,"activeCount":74},[],{"trials":1448,"activeCount":74},[],{"intervention":1450,"totalTrials":108,"cells":1451},"Budesonide",{"EARLY_PHASE1":1452,"PHASE1":1454,"PHASE2":1465,"PHASE3":1467,"PHASE4":1481,"NA":1483},{"trials":1453,"activeCount":74},[],{"trials":1455,"activeCount":74},[1456],{"nctId":1457,"briefTitle":1458,"status":254,"phases":1459,"primaryCompletion":1460,"completion":1460,"start":1461,"enrollment":1173,"conditions":1462,"interventions":1464},"NCT04080713","Cortiment® MMX Pharmacokinetic Study",[63],"2019-09-25","2019-09-16",[1463],"Healthy",[1450],{"trials":1466,"activeCount":74},[],{"trials":1468,"activeCount":74},[1469],{"nctId":1470,"briefTitle":1471,"status":254,"phases":1472,"primaryCompletion":1473,"completion":1474,"start":1475,"enrollment":1476,"conditions":1477,"interventions":1479},"NCT03412682","To Evaluate the Efficacy and Safety of FE 999315 in Japanese Subjects With Mild to Moderate Active Ulcerative Colitis",[65],"2020-05-11","2020-05-26","2018-03-02",274,[1478],"Colitis, Ulcerative",[1450,1450,1480],"Mesalazine",{"trials":1482,"activeCount":74},[],{"trials":1484,"activeCount":74},[],{"intervention":1486,"totalTrials":108,"cells":1487},"Pentasa",{"EARLY_PHASE1":1488,"PHASE1":1490,"PHASE2":1492,"PHASE3":1494,"PHASE4":1513,"NA":1515},{"trials":1489,"activeCount":74},[],{"trials":1491,"activeCount":74},[],{"trials":1493,"activeCount":74},[],{"trials":1495,"activeCount":74},[1496,1503],{"nctId":1497,"briefTitle":1498,"status":543,"phases":1499,"primaryCompletion":479,"completion":479,"start":391,"enrollment":83,"conditions":1500,"interventions":1502},"NCT00862121","A Study With Pentasa in Patients With Active Crohn's Disease",[65],[1501],"Crohn´s Disease",[1486],{"nctId":1504,"briefTitle":1505,"status":254,"phases":1506,"primaryCompletion":1507,"completion":1508,"start":1509,"enrollment":1510,"conditions":1511,"interventions":1512},"NCT00209300","Pentasa Once Daily in Ulcerative Colitis for Maintenance of Remission",[65],"2007-05","2007-06","2005-05",362,[22],[1486],{"trials":1514,"activeCount":74},[],{"trials":1516,"activeCount":74},[],{"intervention":1518,"totalTrials":108,"cells":1519},"Highly Purified Urofollitropin",{"EARLY_PHASE1":1520,"PHASE1":1522,"PHASE2":1524,"PHASE3":1526,"PHASE4":1547,"NA":1549},{"trials":1521,"activeCount":74},[],{"trials":1523,"activeCount":74},[],{"trials":1525,"activeCount":74},[],{"trials":1527,"activeCount":74},[1528,1539],{"nctId":1529,"briefTitle":1530,"status":254,"phases":1531,"primaryCompletion":1532,"completion":1533,"start":371,"enrollment":1534,"conditions":1535,"interventions":1537},"NCT01923194","Evaluation of Efficacy and Safety of Highly Purified Urofollitropin for Ovulation Induction in Chinese Females",[65],"2015-07","2015-08",215,[1536],"Anovulation",[1518,1538],"Recombinant Human Follitropin Alfa",{"nctId":1540,"briefTitle":1541,"status":254,"phases":1542,"primaryCompletion":500,"completion":1543,"start":371,"enrollment":1544,"conditions":1545,"interventions":1546},"NCT01922193","Evaluation of Efficacy and Safety of Highly Purified Urofollitropin in Chinese Females Undergoing an Assisted Reproductive Technology (ART) Program",[65],"2015-04",263,[16],[1518,1538],{"trials":1548,"activeCount":74},[],{"trials":1550,"activeCount":74},[],{"intervention":1538,"totalTrials":108,"cells":1552},{"EARLY_PHASE1":1553,"PHASE1":1555,"PHASE2":1557,"PHASE3":1559,"PHASE4":1569,"NA":1571},{"trials":1554,"activeCount":74},[],{"trials":1556,"activeCount":74},[],{"trials":1558,"activeCount":74},[],{"trials":1560,"activeCount":74},[1561,1565],{"nctId":1529,"briefTitle":1530,"status":254,"phases":1562,"primaryCompletion":1532,"completion":1533,"start":371,"enrollment":1534,"conditions":1563,"interventions":1564},[65],[1536],[1518,1538],{"nctId":1540,"briefTitle":1541,"status":254,"phases":1566,"primaryCompletion":500,"completion":1543,"start":371,"enrollment":1544,"conditions":1567,"interventions":1568},[65],[16],[1518,1538],{"trials":1570,"activeCount":74},[],{"trials":1572,"activeCount":74},[],{"intervention":1574,"totalTrials":108,"cells":1575},"Elobixibat 10 mg",{"EARLY_PHASE1":1576,"PHASE1":1578,"PHASE2":1580,"PHASE3":1582,"PHASE4":1603,"NA":1605},{"trials":1577,"activeCount":74},[],{"trials":1579,"activeCount":74},[],{"trials":1581,"activeCount":74},[],{"trials":1583,"activeCount":74},[1584,1593],{"nctId":1585,"briefTitle":1586,"status":254,"phases":1587,"primaryCompletion":347,"completion":347,"start":1588,"enrollment":1589,"conditions":1590,"interventions":1592},"NCT01895543","Safety and Tolerability Extension Trial for Patients With Chronic Idiopathic Constipation",[65],"2013-09",411,[1591],"Chronic Idiopathic Constipation",[1574],{"nctId":1594,"briefTitle":1595,"status":543,"phases":1596,"primaryCompletion":1597,"completion":1598,"start":987,"enrollment":1599,"conditions":1600,"interventions":1601},"NCT01827592","26 Week Efficacy and Safety Trial for Patients With Chronic Idiopathic Constipation",[65],"2014-03","2014-05",376,[1591],[1574,1602],"Elobixibat 5 mg",{"trials":1604,"activeCount":74},[],{"trials":1606,"activeCount":74},[],{"intervention":1198,"totalTrials":108,"cells":1608},{"EARLY_PHASE1":1609,"PHASE1":1611,"PHASE2":1613,"PHASE3":1615,"PHASE4":1625,"NA":1627},{"trials":1610,"activeCount":74},[],{"trials":1612,"activeCount":74},[],{"trials":1614,"activeCount":74},[],{"trials":1616,"activeCount":74},[1617,1621],{"nctId":1190,"briefTitle":1191,"status":254,"phases":1618,"primaryCompletion":1193,"completion":1193,"start":453,"enrollment":1194,"conditions":1619,"interventions":1620},[65],[1196,25,1175],[1161,1198],{"nctId":1413,"briefTitle":1414,"status":254,"phases":1622,"primaryCompletion":1416,"completion":1416,"start":1417,"enrollment":1418,"conditions":1623,"interventions":1624},[65],[25,1420],[1408,1389,1422],{"trials":1626,"activeCount":74},[],{"trials":1628,"activeCount":74},[],{"intervention":1630,"totalTrials":87,"cells":1631},"FE 999913 vaginal",{"EARLY_PHASE1":1632,"PHASE1":1634,"PHASE2":1636,"PHASE3":1638,"PHASE4":1650,"NA":1652},{"trials":1633,"activeCount":74},[],{"trials":1635,"activeCount":74},[],{"trials":1637,"activeCount":74},[],{"trials":1639,"activeCount":74},[1640],{"nctId":1641,"briefTitle":1642,"status":254,"phases":1643,"primaryCompletion":1644,"completion":1644,"start":1645,"enrollment":1646,"conditions":1647,"interventions":1649},"NCT01710514","A Phase III Study of FE 999913 in Japanese Female Patients Undergoing Fertility Treatment",[65],"2013-08","2012-10",108,[1648],"Luteal Hormone Supplementation",[1630],{"trials":1651,"activeCount":74},[],{"trials":1653,"activeCount":74},[],{"intervention":1655,"totalTrials":87,"cells":1656},"Gonadorelin acetate subcutaneous (SC) 10 μg\u002Fpulse as a fixed dose, administered via. OmniPod pump",{"EARLY_PHASE1":1657,"PHASE1":1659,"PHASE2":1661,"PHASE3":1663,"PHASE4":1677,"NA":1679},{"trials":1658,"activeCount":74},[],{"trials":1660,"activeCount":74},[],{"trials":1662,"activeCount":74},[],{"trials":1664,"activeCount":74},[1665],{"nctId":1666,"briefTitle":1667,"status":254,"phases":1668,"primaryCompletion":1669,"completion":1669,"start":1670,"enrollment":1671,"conditions":1672,"interventions":1674},"NCT01976728","LutrePulse Hypogonadotropic Hypogonadism",[65],"2018-02-23","2014-04-01",39,[1673],"Primary Amenorrhea With Hypogonadotropic Hypogonadism",[1655,1675,1676],"Gonadorelin acetate SC 15 μg\u002Fpulse as a fixed dose, administered via. OmniPod pump","Gonadorelin acetate SC 20 μg\u002Fpulse as a fixed dose, administered via. OmniPod pump",{"trials":1678,"activeCount":74},[],{"trials":1680,"activeCount":74},[],{"intervention":1675,"totalTrials":87,"cells":1682},{"EARLY_PHASE1":1683,"PHASE1":1685,"PHASE2":1687,"PHASE3":1689,"PHASE4":1695,"NA":1697},{"trials":1684,"activeCount":74},[],{"trials":1686,"activeCount":74},[],{"trials":1688,"activeCount":74},[],{"trials":1690,"activeCount":74},[1691],{"nctId":1666,"briefTitle":1667,"status":254,"phases":1692,"primaryCompletion":1669,"completion":1669,"start":1670,"enrollment":1671,"conditions":1693,"interventions":1694},[65],[1673],[1655,1675,1676],{"trials":1696,"activeCount":74},[],{"trials":1698,"activeCount":74},[],{"intervention":1676,"totalTrials":87,"cells":1700},{"EARLY_PHASE1":1701,"PHASE1":1703,"PHASE2":1705,"PHASE3":1707,"PHASE4":1713,"NA":1715},{"trials":1702,"activeCount":74},[],{"trials":1704,"activeCount":74},[],{"trials":1706,"activeCount":74},[],{"trials":1708,"activeCount":74},[1709],{"nctId":1666,"briefTitle":1667,"status":254,"phases":1710,"primaryCompletion":1669,"completion":1669,"start":1670,"enrollment":1671,"conditions":1711,"interventions":1712},[65],[1673],[1655,1675,1676],{"trials":1714,"activeCount":74},[],{"trials":1716,"activeCount":74},[],{"intervention":1718,"totalTrials":87,"cells":1719},"desmopressin acetate",{"EARLY_PHASE1":1720,"PHASE1":1722,"PHASE2":1724,"PHASE3":1726,"PHASE4":1736,"NA":1738},{"trials":1721,"activeCount":74},[],{"trials":1723,"activeCount":74},[],{"trials":1725,"activeCount":74},[],{"trials":1727,"activeCount":74},[1728],{"nctId":1729,"briefTitle":1730,"status":254,"phases":1731,"primaryCompletion":1732,"completion":1732,"start":1507,"enrollment":1733,"conditions":1734,"interventions":1735},"NCT00477490","Efficacy and Safety of Desmopressin Melt for the Treatment of Nocturia",[65],"2008-02",799,[19],[1718],{"trials":1737,"activeCount":74},[],{"trials":1739,"activeCount":74},[],{"intervention":1298,"totalTrials":87,"cells":1741},{"EARLY_PHASE1":1742,"PHASE1":1744,"PHASE2":1746,"PHASE3":1748,"PHASE4":1754,"NA":1756},{"trials":1743,"activeCount":74},[],{"trials":1745,"activeCount":74},[],{"trials":1747,"activeCount":74},[],{"trials":1749,"activeCount":74},[1750],{"nctId":1293,"briefTitle":1294,"status":254,"phases":1751,"primaryCompletion":1193,"completion":957,"start":1012,"enrollment":1111,"conditions":1752,"interventions":1753},[65],[1287],[1272,1298],{"trials":1755,"activeCount":74},[],{"trials":1757,"activeCount":74},[],{"intervention":1759,"totalTrials":87,"cells":1760},"FE 999049 + GnRH agonist",{"EARLY_PHASE1":1761,"PHASE1":1763,"PHASE2":1765,"PHASE3":1767,"PHASE4":1779,"NA":1781},{"trials":1762,"activeCount":74},[],{"trials":1764,"activeCount":74},[],{"trials":1766,"activeCount":74},[],{"trials":1768,"activeCount":74},[1769],{"nctId":1770,"briefTitle":1771,"status":254,"phases":1772,"primaryCompletion":1773,"completion":1773,"start":1774,"enrollment":1775,"conditions":1776,"interventions":1777},"NCT03809429","Follitropin Delta in Long GnRH Agonist and GnRH Antagonist Protocols (BEYOND)",[65],"2022-02-16","2019-04-29",437,[28],[1759,1778],"FE 999049 + GnRH antagonist",{"trials":1780,"activeCount":74},[],{"trials":1782,"activeCount":74},[],{"intervention":1778,"totalTrials":87,"cells":1784},{"EARLY_PHASE1":1785,"PHASE1":1787,"PHASE2":1789,"PHASE3":1791,"PHASE4":1797,"NA":1799},{"trials":1786,"activeCount":74},[],{"trials":1788,"activeCount":74},[],{"trials":1790,"activeCount":74},[],{"trials":1792,"activeCount":74},[1793],{"nctId":1770,"briefTitle":1771,"status":254,"phases":1794,"primaryCompletion":1773,"completion":1773,"start":1774,"enrollment":1775,"conditions":1795,"interventions":1796},[65],[28],[1759,1778],{"trials":1798,"activeCount":74},[],{"trials":1800,"activeCount":74},[],{"intervention":1802,"totalTrials":87,"cells":1803},"highly purified human chorionic gonadotropin",{"EARLY_PHASE1":1804,"PHASE1":1806,"PHASE2":1808,"PHASE3":1810,"PHASE4":1823,"NA":1825},{"trials":1805,"activeCount":74},[],{"trials":1807,"activeCount":74},[],{"trials":1809,"activeCount":74},[],{"trials":1811,"activeCount":74},[1812],{"nctId":1813,"briefTitle":1814,"status":254,"phases":1815,"primaryCompletion":1816,"completion":1817,"start":1818,"enrollment":1819,"conditions":1820,"interventions":1821},"NCT02449889","A Randomised Trial Using Highly Purified Human Chorionic Gonadotropin (HP-hCG) and Recombinant Human Chorionic Gonadotropin (rhCG) in Women Undergoing Controlled Ovarian Stimulation",[65],"2017-07-09","2018-03-01","2016-04",176,[16],[1802,1822],"recombinant human chorionic gonadotropin",{"trials":1824,"activeCount":74},[],{"trials":1826,"activeCount":74},[],{"intervention":1822,"totalTrials":87,"cells":1828},{"EARLY_PHASE1":1829,"PHASE1":1831,"PHASE2":1833,"PHASE3":1835,"PHASE4":1841,"NA":1843},{"trials":1830,"activeCount":74},[],{"trials":1832,"activeCount":74},[],{"trials":1834,"activeCount":74},[],{"trials":1836,"activeCount":74},[1837],{"nctId":1813,"briefTitle":1814,"status":254,"phases":1838,"primaryCompletion":1816,"completion":1817,"start":1818,"enrollment":1819,"conditions":1839,"interventions":1840},[65],[16],[1802,1822],{"trials":1842,"activeCount":74},[],{"trials":1844,"activeCount":74},[],{"intervention":1846,"totalTrials":87,"cells":1847},"Degarelix 240 mg \u002F 80 mg",{"EARLY_PHASE1":1848,"PHASE1":1850,"PHASE2":1852,"PHASE3":1854,"PHASE4":1864,"NA":1866},{"trials":1849,"activeCount":74},[],{"trials":1851,"activeCount":74},[],{"trials":1853,"activeCount":74},[],{"trials":1855,"activeCount":74},[1856],{"nctId":1857,"briefTitle":1858,"status":254,"phases":1859,"primaryCompletion":1860,"completion":1861,"start":440,"enrollment":381,"conditions":1862,"interventions":1863},"NCT00801242","Intermittent Treatment With Degarelix of Patients Suffering From Prostate Cancer",[65],"2012-06","2013-07",[14],[1846],{"trials":1865,"activeCount":74},[],{"trials":1867,"activeCount":74},[],{"intervention":1869,"totalTrials":87,"cells":1870},"Mesalazine slow-release granules",{"EARLY_PHASE1":1871,"PHASE1":1873,"PHASE2":1875,"PHASE3":1877,"PHASE4":1888,"NA":1890},{"trials":1872,"activeCount":74},[],{"trials":1874,"activeCount":74},[],{"trials":1876,"activeCount":74},[],{"trials":1878,"activeCount":74},[1879],{"nctId":1880,"briefTitle":1881,"status":254,"phases":1882,"primaryCompletion":546,"completion":546,"start":1883,"enrollment":1884,"conditions":1885,"interventions":1886},"NCT00737789","Mesalazine 4g Once Daily Versus 4g in Two Divided Doses in Active Ulcerative Colitis.",[65],"2008-11",206,[22],[1869,1887],"Mesalazine liquid enema",{"trials":1889,"activeCount":74},[],{"trials":1891,"activeCount":74},[],{"intervention":1887,"totalTrials":87,"cells":1893},{"EARLY_PHASE1":1894,"PHASE1":1896,"PHASE2":1898,"PHASE3":1900,"PHASE4":1906,"NA":1908},{"trials":1895,"activeCount":74},[],{"trials":1897,"activeCount":74},[],{"trials":1899,"activeCount":74},[],{"trials":1901,"activeCount":74},[1902],{"nctId":1880,"briefTitle":1881,"status":254,"phases":1903,"primaryCompletion":546,"completion":546,"start":1883,"enrollment":1884,"conditions":1904,"interventions":1905},[65],[22],[1869,1887],{"trials":1907,"activeCount":74},[],{"trials":1909,"activeCount":74},[],{"intervention":1911,"totalTrials":87,"cells":1912},"Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Oral Solution",{"EARLY_PHASE1":1913,"PHASE1":1915,"PHASE2":1917,"PHASE3":1919,"PHASE4":1932,"NA":1934},{"trials":1914,"activeCount":74},[],{"trials":1916,"activeCount":74},[],{"trials":1918,"activeCount":74},[],{"trials":1920,"activeCount":74},[1921],{"nctId":1922,"briefTitle":1923,"status":254,"phases":1924,"primaryCompletion":1925,"completion":1926,"start":1927,"enrollment":1928,"conditions":1929,"interventions":1930},"NCT03017235","A Study Comparing the Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Oral Solution With PREPOPIK® for Colon Cleansing in Preparation for Colonoscopy",[65],"2017-09-15","2017-10-12","2017-02-20",917,[214],[1911,1931],"Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Powder",{"trials":1933,"activeCount":74},[],{"trials":1935,"activeCount":74},[],{"intervention":1931,"totalTrials":87,"cells":1937},{"EARLY_PHASE1":1938,"PHASE1":1940,"PHASE2":1942,"PHASE3":1944,"PHASE4":1950,"NA":1952},{"trials":1939,"activeCount":74},[],{"trials":1941,"activeCount":74},[],{"trials":1943,"activeCount":74},[],{"trials":1945,"activeCount":74},[1946],{"nctId":1922,"briefTitle":1923,"status":254,"phases":1947,"primaryCompletion":1925,"completion":1926,"start":1927,"enrollment":1928,"conditions":1948,"interventions":1949},[65],[214],[1911,1931],{"trials":1951,"activeCount":74},[],{"trials":1953,"activeCount":74},[],{"intervention":1955,"totalTrials":87,"cells":1956},"Elobixibat 10 mg\u002Fday",{"EARLY_PHASE1":1957,"PHASE1":1959,"PHASE2":1961,"PHASE3":1963,"PHASE4":1974,"NA":1976},{"trials":1958,"activeCount":74},[],{"trials":1960,"activeCount":74},[],{"trials":1962,"activeCount":74},[],{"trials":1964,"activeCount":74},[1965],{"nctId":1966,"briefTitle":1967,"status":543,"phases":1968,"primaryCompletion":1597,"completion":1969,"start":987,"enrollment":1970,"conditions":1971,"interventions":1972},"NCT01833065","Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation",[65],"2014-04",314,[1591],[1955,1973],"Elobixibat 5 mg\u002Fday",{"trials":1975,"activeCount":74},[],{"trials":1977,"activeCount":74},[],{"intervention":1973,"totalTrials":87,"cells":1979},{"EARLY_PHASE1":1980,"PHASE1":1982,"PHASE2":1984,"PHASE3":1986,"PHASE4":1992,"NA":1994},{"trials":1981,"activeCount":74},[],{"trials":1983,"activeCount":74},[],{"trials":1985,"activeCount":74},[],{"trials":1987,"activeCount":74},[1988],{"nctId":1966,"briefTitle":1967,"status":543,"phases":1989,"primaryCompletion":1597,"completion":1969,"start":987,"enrollment":1970,"conditions":1990,"interventions":1991},[65],[1591],[1955,1973],{"trials":1993,"activeCount":74},[],{"trials":1995,"activeCount":74},[],{"intervention":1997,"totalTrials":87,"cells":1998},"Endometrin",{"EARLY_PHASE1":1999,"PHASE1":2001,"PHASE2":2003,"PHASE3":2005,"PHASE4":2018,"NA":2020},{"trials":2000,"activeCount":74},[],{"trials":2002,"activeCount":74},[],{"trials":2004,"activeCount":74},[],{"trials":2006,"activeCount":74},[2007],{"nctId":2008,"briefTitle":2009,"status":254,"phases":2010,"primaryCompletion":1417,"completion":2011,"start":2012,"enrollment":2013,"conditions":2014,"interventions":2016},"NCT00296478","Multi-Center, Randomized, Open-Label, Parallel Group Study of a Vaginal Micronized Progesterone Tablet (Endometrin®) Compared to Crinone 8% Vaginal Gel in Female Patients Undergoing In-Vitro Fertilization (IVF)",[65],"2006-07","2005-07",1211,[2015],"Fertility",[1997,1997,2017],"Crinone",{"trials":2019,"activeCount":74},[],{"trials":2021,"activeCount":74},[],{"intervention":2017,"totalTrials":87,"cells":2023},{"EARLY_PHASE1":2024,"PHASE1":2026,"PHASE2":2028,"PHASE3":2030,"PHASE4":2036,"NA":2038},{"trials":2025,"activeCount":74},[],{"trials":2027,"activeCount":74},[],{"trials":2029,"activeCount":74},[],{"trials":2031,"activeCount":74},[2032],{"nctId":2008,"briefTitle":2009,"status":254,"phases":2033,"primaryCompletion":1417,"completion":2011,"start":2012,"enrollment":2013,"conditions":2034,"interventions":2035},[65],[2015],[1997,1997,2017],{"trials":2037,"activeCount":74},[],{"trials":2039,"activeCount":74},[],{"intervention":2041,"totalTrials":87,"cells":2042},"Genotropin",{"EARLY_PHASE1":2043,"PHASE1":2045,"PHASE2":2047,"PHASE3":2049,"PHASE4":2060,"NA":2062},{"trials":2044,"activeCount":74},[],{"trials":2046,"activeCount":74},[],{"trials":2048,"activeCount":74},[],{"trials":2050,"activeCount":74},[2051],{"nctId":2052,"briefTitle":2053,"status":254,"phases":2054,"primaryCompletion":1860,"completion":989,"start":439,"enrollment":2055,"conditions":2056,"interventions":2058},"NCT00884000","A Study of Zomacton in Children With Growth Hormone Deficiency",[65],165,[2057],"Growth Hormone Deficiency",[2041,2059],"Zomacton",{"trials":2061,"activeCount":74},[],{"trials":2063,"activeCount":74},[],{"intervention":1088,"totalTrials":87,"cells":2065},{"EARLY_PHASE1":2066,"PHASE1":2068,"PHASE2":2070,"PHASE3":2072,"PHASE4":2078,"NA":2080},{"trials":2067,"activeCount":74},[],{"trials":2069,"activeCount":74},[],{"trials":2071,"activeCount":74},[],{"trials":2073,"activeCount":74},[2074],{"nctId":1080,"briefTitle":1081,"status":254,"phases":2075,"primaryCompletion":1083,"completion":1083,"start":1084,"enrollment":1085,"conditions":2076,"interventions":2077},[65],[28],[418,1088],{"trials":2079,"activeCount":74},[],{"trials":2081,"activeCount":74},[],{"intervention":2083,"totalTrials":87,"cells":2084},"Desmopressin Oral Melt",{"EARLY_PHASE1":2085,"PHASE1":2087,"PHASE2":2089,"PHASE3":2091,"PHASE4":2102,"NA":2104},{"trials":2086,"activeCount":74},[],{"trials":2088,"activeCount":74},[],{"trials":2090,"activeCount":74},[],{"trials":2092,"activeCount":74},[2093],{"nctId":2094,"briefTitle":2095,"status":254,"phases":2096,"primaryCompletion":2097,"completion":1254,"start":570,"enrollment":83,"conditions":2098,"interventions":2100},"NCT01280188","A Study of Minirin Melt in Japanese Patients With Central Diabetes Insipidus (CDI).",[65],"2011-08",[2099],"Central Diabetes Insipidus",[2083,2101],"Desmopressin intranasal",{"trials":2103,"activeCount":74},[],{"trials":2105,"activeCount":74},[],{"intervention":2101,"totalTrials":87,"cells":2107},{"EARLY_PHASE1":2108,"PHASE1":2110,"PHASE2":2112,"PHASE3":2114,"PHASE4":2120,"NA":2122},{"trials":2109,"activeCount":74},[],{"trials":2111,"activeCount":74},[],{"trials":2113,"activeCount":74},[],{"trials":2115,"activeCount":74},[2116],{"nctId":2094,"briefTitle":2095,"status":254,"phases":2117,"primaryCompletion":2097,"completion":1254,"start":570,"enrollment":83,"conditions":2118,"interventions":2119},[65],[2099],[2083,2101],{"trials":2121,"activeCount":74},[],{"trials":2123,"activeCount":74},[],{"intervention":2125,"totalTrials":87,"cells":2126},"Leuprolide 7.5 mg",{"EARLY_PHASE1":2127,"PHASE1":2129,"PHASE2":2131,"PHASE3":2133,"PHASE4":2142,"NA":2144},{"trials":2128,"activeCount":74},[],{"trials":2130,"activeCount":74},[],{"trials":2132,"activeCount":74},[],{"trials":2134,"activeCount":74},[2135],{"nctId":2136,"briefTitle":2137,"status":254,"phases":2138,"primaryCompletion":2139,"completion":2139,"start":894,"enrollment":586,"conditions":2140,"interventions":2141},"NCT00295750","The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer",[65],"2007-10",[14],[1016,1016,2125],{"trials":2143,"activeCount":74},[],{"trials":2145,"activeCount":74},[],{"intervention":2147,"totalTrials":87,"cells":2148},"Degarelix 80 mg \u002F Degarelix 80 mg",{"EARLY_PHASE1":2149,"PHASE1":2151,"PHASE2":2153,"PHASE3":2155,"PHASE4":2169,"NA":2171},{"trials":2150,"activeCount":74},[],{"trials":2152,"activeCount":74},[],{"trials":2154,"activeCount":74},[],{"trials":2156,"activeCount":74},[2157],{"nctId":2158,"briefTitle":2159,"status":254,"phases":2160,"primaryCompletion":2161,"completion":958,"start":2162,"enrollment":2163,"conditions":2164,"interventions":2165},"NCT00451958","A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy",[65],"2011-10","2007-03",386,[14],[2147,2166,2167,2168],"Degarelix 160 mg \u002F Degarelix 160 mg","Leuprolide 7.5 mg \u002F Degarelix 80 mg","Leuprolide 7.5 mg \u002F Degarelix 160 mg",{"trials":2170,"activeCount":74},[],{"trials":2172,"activeCount":74},[],{"intervention":2166,"totalTrials":87,"cells":2174},{"EARLY_PHASE1":2175,"PHASE1":2177,"PHASE2":2179,"PHASE3":2181,"PHASE4":2187,"NA":2189},{"trials":2176,"activeCount":74},[],{"trials":2178,"activeCount":74},[],{"trials":2180,"activeCount":74},[],{"trials":2182,"activeCount":74},[2183],{"nctId":2158,"briefTitle":2159,"status":254,"phases":2184,"primaryCompletion":2161,"completion":958,"start":2162,"enrollment":2163,"conditions":2185,"interventions":2186},[65],[14],[2147,2166,2167,2168],{"trials":2188,"activeCount":74},[],{"trials":2190,"activeCount":74},[],{"intervention":2167,"totalTrials":87,"cells":2192},{"EARLY_PHASE1":2193,"PHASE1":2195,"PHASE2":2197,"PHASE3":2199,"PHASE4":2205,"NA":2207},{"trials":2194,"activeCount":74},[],{"trials":2196,"activeCount":74},[],{"trials":2198,"activeCount":74},[],{"trials":2200,"activeCount":74},[2201],{"nctId":2158,"briefTitle":2159,"status":254,"phases":2202,"primaryCompletion":2161,"completion":958,"start":2162,"enrollment":2163,"conditions":2203,"interventions":2204},[65],[14],[2147,2166,2167,2168],{"trials":2206,"activeCount":74},[],{"trials":2208,"activeCount":74},[],{"intervention":2168,"totalTrials":87,"cells":2210},{"EARLY_PHASE1":2211,"PHASE1":2213,"PHASE2":2215,"PHASE3":2217,"PHASE4":2223,"NA":2225},{"trials":2212,"activeCount":74},[],{"trials":2214,"activeCount":74},[],{"trials":2216,"activeCount":74},[],{"trials":2218,"activeCount":74},[2219],{"nctId":2158,"briefTitle":2159,"status":254,"phases":2220,"primaryCompletion":2161,"completion":958,"start":2162,"enrollment":2163,"conditions":2221,"interventions":2222},[65],[14],[2147,2166,2167,2168],{"trials":2224,"activeCount":74},[],{"trials":2226,"activeCount":74},[],{"intervention":2228,"totalTrials":87,"cells":2229},"MENOPUR solution for injection in pre-filled pen, 1200 IU\u002F1.92 mL",{"EARLY_PHASE1":2230,"PHASE1":2232,"PHASE2":2234,"PHASE3":2236,"PHASE4":2249,"NA":2251},{"trials":2231,"activeCount":74},[],{"trials":2233,"activeCount":74},[],{"trials":2235,"activeCount":74},[],{"trials":2237,"activeCount":74},[2238],{"nctId":2239,"briefTitle":2240,"status":254,"phases":2241,"primaryCompletion":2242,"completion":2243,"start":2244,"enrollment":2245,"conditions":2246,"interventions":2247},"NCT04163458","Comparison of MENOPUR Liquid and Powder in Women Undergoing Assisted Reproductive Technology (ART)",[65],"2021-05-28","2021-07-16","2019-10-25",405,[16],[2228,2248],"MENOPUR powder and solvent for solution for injection, 75 IU",{"trials":2250,"activeCount":74},[],{"trials":2252,"activeCount":74},[],{"intervention":2248,"totalTrials":87,"cells":2254},{"EARLY_PHASE1":2255,"PHASE1":2257,"PHASE2":2259,"PHASE3":2261,"PHASE4":2267,"NA":2269},{"trials":2256,"activeCount":74},[],{"trials":2258,"activeCount":74},[],{"trials":2260,"activeCount":74},[],{"trials":2262,"activeCount":74},[2263],{"nctId":2239,"briefTitle":2240,"status":254,"phases":2264,"primaryCompletion":2242,"completion":2243,"start":2244,"enrollment":2245,"conditions":2265,"interventions":2266},[65],[16],[2228,2248],{"trials":2268,"activeCount":74},[],{"trials":2270,"activeCount":74},[],{"intervention":2272,"totalTrials":87,"cells":2273},"RBX2660",{"EARLY_PHASE1":2274,"PHASE1":2276,"PHASE2":2278,"PHASE3":2280,"PHASE4":2291,"NA":2293},{"trials":2275,"activeCount":74},[],{"trials":2277,"activeCount":74},[],{"trials":2279,"activeCount":74},[],{"trials":2281,"activeCount":74},[2282],{"nctId":2283,"briefTitle":2284,"status":254,"phases":2285,"primaryCompletion":2286,"completion":2286,"start":2287,"enrollment":11,"conditions":2288,"interventions":2290},"NCT05831189","A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection",[65],"2025-01-17","2023-04-21",[2289],"Clostridium Difficile Infection Recurrence",[2272],{"trials":2292,"activeCount":74},[],{"trials":2294,"activeCount":74},[],{"intervention":2296,"totalTrials":87,"cells":2297},"FE 999169",{"EARLY_PHASE1":2298,"PHASE1":2300,"PHASE2":2302,"PHASE3":2304,"PHASE4":2316,"NA":2318},{"trials":2299,"activeCount":74},[],{"trials":2301,"activeCount":74},[],{"trials":2303,"activeCount":74},[],{"trials":2305,"activeCount":74},[2306],{"nctId":2307,"briefTitle":2308,"status":254,"phases":2309,"primaryCompletion":414,"completion":414,"start":2310,"enrollment":2311,"conditions":2312,"interventions":2314},"NCT02215954","A Phase III Study With FE 999169 Versus Niflec for Colon Cleansing",[65],"2014-09",637,[2313],"Colon Cleansing in Preparation for Colonoscopy",[2296,2315],"Niflec",{"trials":2317,"activeCount":74},[],{"trials":2319,"activeCount":74},[],{"intervention":2315,"totalTrials":87,"cells":2321},{"EARLY_PHASE1":2322,"PHASE1":2324,"PHASE2":2326,"PHASE3":2328,"PHASE4":2334,"NA":2336},{"trials":2323,"activeCount":74},[],{"trials":2325,"activeCount":74},[],{"trials":2327,"activeCount":74},[],{"trials":2329,"activeCount":74},[2330],{"nctId":2307,"briefTitle":2308,"status":254,"phases":2331,"primaryCompletion":414,"completion":414,"start":2310,"enrollment":2311,"conditions":2332,"interventions":2333},[65],[2313],[2296,2315],{"trials":2335,"activeCount":74},[],{"trials":2337,"activeCount":74},[],{"intervention":2339,"totalTrials":87,"cells":2340},"Mesalazine Enema",{"EARLY_PHASE1":2341,"PHASE1":2343,"PHASE2":2345,"PHASE3":2347,"PHASE4":2359,"NA":2361},{"trials":2342,"activeCount":74},[],{"trials":2344,"activeCount":74},[],{"trials":2346,"activeCount":74},[],{"trials":2348,"activeCount":74},[2349],{"nctId":2350,"briefTitle":2351,"status":254,"phases":2352,"primaryCompletion":2353,"completion":2354,"start":2355,"enrollment":2356,"conditions":2357,"interventions":2358},"NCT02368717","An Efficacy and Safety Study of PENTASA in Chinese Patients With Left-sided Active Ulcerative Colitis Followed by a 24-Week Open-Label Extension Phase",[65],"2017-01-05","2017-07-25","2015-03",281,[22],[2339],{"trials":2360,"activeCount":74},[],{"trials":2362,"activeCount":74},[],{"intervention":2364,"totalTrials":87,"cells":2365},"selepressin",{"EARLY_PHASE1":2366,"PHASE1":2368,"PHASE2":2370,"PHASE3":2372,"PHASE4":2384,"NA":2386},{"trials":2367,"activeCount":74},[],{"trials":2369,"activeCount":74},[],{"trials":2371,"activeCount":74},[],{"trials":2373,"activeCount":74},[2374],{"nctId":2375,"briefTitle":2376,"status":543,"phases":2377,"primaryCompletion":2378,"completion":2379,"start":1532,"enrollment":2380,"conditions":2381,"interventions":2383},"NCT02508649","Selepressin Evaluation Programme for Sepsis-Induced Shock - Adaptive Clinical Trial",[64,65],"2017-10-03","2018-02-26",868,[2382],"Septic Shock",[2364],{"trials":2385,"activeCount":74},[],{"trials":2387,"activeCount":74},[],{"intervention":1233,"totalTrials":87,"cells":2389},{"EARLY_PHASE1":2390,"PHASE1":2392,"PHASE2":2394,"PHASE3":2396,"PHASE4":2402,"NA":2404},{"trials":2391,"activeCount":74},[],{"trials":2393,"activeCount":74},[],{"trials":2395,"activeCount":74},[],{"trials":2397,"activeCount":74},[2398],{"nctId":1224,"briefTitle":1225,"status":254,"phases":2399,"primaryCompletion":1227,"completion":1227,"start":1228,"enrollment":1229,"conditions":2400,"interventions":2401},[64,65],[1231],[1233,1234],{"trials":2403,"activeCount":74},[],{"trials":2405,"activeCount":74},[],{"intervention":2407,"totalTrials":87,"cells":2408},"5-ASA",{"EARLY_PHASE1":2409,"PHASE1":2411,"PHASE2":2413,"PHASE3":2415,"PHASE4":2425,"NA":2427},{"trials":2410,"activeCount":74},[],{"trials":2412,"activeCount":74},[],{"trials":2414,"activeCount":74},[],{"trials":2416,"activeCount":74},[2417],{"nctId":2418,"briefTitle":2419,"status":254,"phases":2420,"primaryCompletion":949,"completion":949,"start":2139,"enrollment":289,"conditions":2421,"interventions":2424},"NCT00603733","Canadian Active & Maintenance Modified Pentasa Study",[65],[2422,2423],"Active Ulcerative Colitis","Remission of Ulcerative Colitis",[2407,2407],{"trials":2426,"activeCount":74},[],{"trials":2428,"activeCount":74},[],{"intervention":1602,"totalTrials":87,"cells":2430},{"EARLY_PHASE1":2431,"PHASE1":2433,"PHASE2":2435,"PHASE3":2437,"PHASE4":2443,"NA":2445},{"trials":2432,"activeCount":74},[],{"trials":2434,"activeCount":74},[],{"trials":2436,"activeCount":74},[],{"trials":2438,"activeCount":74},[2439],{"nctId":1594,"briefTitle":1595,"status":543,"phases":2440,"primaryCompletion":1597,"completion":1598,"start":987,"enrollment":1599,"conditions":2441,"interventions":2442},[65],[1591],[1574,1602],{"trials":2444,"activeCount":74},[],{"trials":2446,"activeCount":74},[],{"intervention":2448,"totalTrials":87,"cells":2449},"Degarelix 240\u002F80 mg",{"EARLY_PHASE1":2450,"PHASE1":2452,"PHASE2":2454,"PHASE3":2456,"PHASE4":2467,"NA":2469},{"trials":2451,"activeCount":74},[],{"trials":2453,"activeCount":74},[],{"trials":2455,"activeCount":74},[],{"trials":2457,"activeCount":74},[2458],{"nctId":2459,"briefTitle":2460,"status":254,"phases":2461,"primaryCompletion":2462,"completion":2462,"start":2463,"enrollment":2464,"conditions":2465,"interventions":2466},"NCT01071915","Efficacy and Safety of Degarelix One Month Dosing Regimen in Korean Patients With Prostate Cancer",[65],"2011-11","2010-03",157,[14],[2448],{"trials":2468,"activeCount":74},[],{"trials":2470,"activeCount":74},[],{"intervention":2472,"totalTrials":87,"cells":2473},"Desmopressin Melt",{"EARLY_PHASE1":2474,"PHASE1":2476,"PHASE2":2478,"PHASE3":2480,"PHASE4":2490,"NA":2492},{"trials":2475,"activeCount":74},[],{"trials":2477,"activeCount":74},[],{"trials":2479,"activeCount":74},[],{"trials":2481,"activeCount":74},[2482],{"nctId":2483,"briefTitle":2484,"status":254,"phases":2485,"primaryCompletion":480,"completion":480,"start":2486,"enrollment":2487,"conditions":2488,"interventions":2489},"NCT00615836","An Extension Study Investigating the Efficacy and Safety of a Fast-Dissolving (\"Melt\") Formulation of Desmopressin for the Treatment of Nocturia in Adults",[65],"2007-12",554,[19],[2472],{"trials":2491,"activeCount":74},[],{"trials":2493,"activeCount":74},[],{"intervention":1116,"totalTrials":87,"cells":2495},{"EARLY_PHASE1":2496,"PHASE1":2498,"PHASE2":2500,"PHASE3":2502,"PHASE4":2508,"NA":2510},{"trials":2497,"activeCount":74},[],{"trials":2499,"activeCount":74},[],{"trials":2501,"activeCount":74},[],{"trials":2503,"activeCount":74},[2504],{"nctId":1108,"briefTitle":1109,"status":254,"phases":2505,"primaryCompletion":949,"completion":656,"start":570,"enrollment":1111,"conditions":2506,"interventions":2507},[65],[1113],[1115,1116],{"trials":2509,"activeCount":74},[],{"trials":2511,"activeCount":74},[],{"intervention":575,"totalTrials":87,"cells":2513},{"EARLY_PHASE1":2514,"PHASE1":2516,"PHASE2":2518,"PHASE3":2520,"PHASE4":2526,"NA":2528},{"trials":2515,"activeCount":74},[],{"trials":2517,"activeCount":74},[],{"trials":2519,"activeCount":74},[],{"trials":2521,"activeCount":74},[2522],{"nctId":567,"briefTitle":568,"status":254,"phases":2523,"primaryCompletion":452,"completion":570,"start":571,"enrollment":572,"conditions":2524,"interventions":2525},[65],[16],[575,576],{"trials":2527,"activeCount":74},[],{"trials":2529,"activeCount":74},[],{"intervention":2531,"totalTrials":87,"cells":2532},"Desmopressin ODT 25 μg",{"EARLY_PHASE1":2533,"PHASE1":2535,"PHASE2":2537,"PHASE3":2539,"PHASE4":2551,"NA":2553},{"trials":2534,"activeCount":74},[],{"trials":2536,"activeCount":74},[],{"trials":2538,"activeCount":74},[],{"trials":2540,"activeCount":74},[2541],{"nctId":2542,"briefTitle":2543,"status":254,"phases":2544,"primaryCompletion":2545,"completion":2545,"start":2546,"enrollment":2547,"conditions":2548,"interventions":2549},"NCT03051009","Trial Investigating the Long Term Safety and Tolerability of Desmopressin Orally Disintegrating Tablets (ODT) for Nocturia Due to Nocturnal Polyuria in Japanese Subjects",[65],"2018-09-11","2017-01-11",503,[19],[2531,2550],"Desmopressin ODT 50 μg",{"trials":2552,"activeCount":74},[],{"trials":2554,"activeCount":74},[],{"intervention":2550,"totalTrials":87,"cells":2556},{"EARLY_PHASE1":2557,"PHASE1":2559,"PHASE2":2561,"PHASE3":2563,"PHASE4":2569,"NA":2571},{"trials":2558,"activeCount":74},[],{"trials":2560,"activeCount":74},[],{"trials":2562,"activeCount":74},[],{"trials":2564,"activeCount":74},[2565],{"nctId":2542,"briefTitle":2543,"status":254,"phases":2566,"primaryCompletion":2545,"completion":2545,"start":2546,"enrollment":2547,"conditions":2567,"interventions":2568},[65],[19],[2531,2550],{"trials":2570,"activeCount":74},[],{"trials":2572,"activeCount":74},[],{"intervention":2574,"totalTrials":87,"cells":2575},"Progesterone vaginal ring",{"EARLY_PHASE1":2576,"PHASE1":2578,"PHASE2":2580,"PHASE3":2582,"PHASE4":2594,"NA":2596},{"trials":2577,"activeCount":74},[],{"trials":2579,"activeCount":74},[],{"trials":2581,"activeCount":74},[],{"trials":2583,"activeCount":74},[2584],{"nctId":2585,"briefTitle":2586,"status":254,"phases":2587,"primaryCompletion":2588,"completion":2588,"start":2589,"enrollment":2590,"conditions":2591,"interventions":2593},"NCT03565211","Clinical Safety Study of the Progesterone Vaginal Ring in Women Undergoing Assisted Reproductive Technology Procedures",[65],"2019-07-29","2018-07-26",352,[2592],"Progesterone Supplementation in Women Undergoing ART",[2574],{"trials":2595,"activeCount":74},[],{"trials":2597,"activeCount":74},[],{"intervention":2599,"totalTrials":70,"cells":2600},"Semapimod",{"EARLY_PHASE1":2601,"PHASE1":2603,"PHASE2":2605,"PHASE3":2645,"PHASE4":2647,"NA":2649},{"trials":2602,"activeCount":74},[],{"trials":2604,"activeCount":74},[],{"trials":2606,"activeCount":74},[2607,2617,2627,2637],{"nctId":2608,"briefTitle":2609,"status":254,"phases":2610,"primaryCompletion":2611,"completion":2612,"start":2613,"enrollment":2614,"conditions":2615,"interventions":2616},"NCT00740103","Long-term Study of Semapimod (CNI-1493) for Treatment of Crohn's Disease",[64],"2004-07","2004-09","2002-12",119,[30],[2599],{"nctId":2618,"briefTitle":2619,"status":543,"phases":2620,"primaryCompletion":1403,"completion":1403,"start":2621,"enrollment":2622,"conditions":2623,"interventions":2625},"NCT00038766","CNI-1493 for Treatment of Moderate to Severe Crohn's Disease",[64],"2002-06",33,[2624],"Crohn Disease",[2626,2626],"semapimod",{"nctId":2628,"briefTitle":2629,"status":254,"phases":2630,"primaryCompletion":2631,"completion":2632,"start":2633,"enrollment":2634,"conditions":2635,"interventions":2636},"NCT00739986","Semapimod for Treatment of Moderate to Severe Crohn's Disease 1 or 3 Days' Treatment Versus Placebo",[64],"2004-06","2004-08","2002-10",152,[30],[2599,2599],{"nctId":2638,"briefTitle":2639,"status":254,"phases":2640,"primaryCompletion":2641,"completion":2641,"start":2642,"enrollment":23,"conditions":2643,"interventions":2644},"NCT00741910","Extension Study of Semapimod 60 mg IV x 3 Days",[64],"2006-06","2003-07",[30],[2599],{"trials":2646,"activeCount":74},[],{"trials":2648,"activeCount":74},[],{"trials":2650,"activeCount":74},[],{"intervention":2652,"totalTrials":465,"cells":2653},"Barusiban",{"EARLY_PHASE1":2654,"PHASE1":2656,"PHASE2":2658,"PHASE3":2689,"PHASE4":2691,"NA":2693},{"trials":2655,"activeCount":74},[],{"trials":2657,"activeCount":74},[],{"trials":2659,"activeCount":74},[2660,2671,2680],{"nctId":2661,"briefTitle":2662,"status":254,"phases":2663,"primaryCompletion":297,"completion":2664,"start":2665,"enrollment":2666,"conditions":2667,"interventions":2669},"NCT00587327","Effect of Oxytocin and Vasopressin Antagonists on Uterine Contractions",[64],"2008-09","2007-11",125,[2668],"In Vitro Fertilisation (IVF) Treatment",[2652,2670],"Atosiban",{"nctId":2672,"briefTitle":2673,"status":254,"phases":2674,"primaryCompletion":2675,"completion":347,"start":2676,"enrollment":2677,"conditions":2678,"interventions":2679},"NCT01723982","Barusiban Subcutaneously for Reducing Implantation Failure Due to Uterine Contractions",[64],"2014-10","2012-11",256,[16],[2652],{"nctId":2681,"briefTitle":2682,"status":254,"phases":2683,"primaryCompletion":480,"completion":2684,"start":2685,"enrollment":2686,"conditions":2687,"interventions":2688},"NCT01043120","Effect of Oxytocin Antagonist on Reduction of Uterine Contractions",[64],"2010-12","2010-02",99,[2668],[2652],{"trials":2690,"activeCount":74},[],{"trials":2692,"activeCount":74},[],{"trials":2694,"activeCount":74},[],{"intervention":2696,"totalTrials":108,"cells":2697},"FE 999302",{"EARLY_PHASE1":2698,"PHASE1":2700,"PHASE2":2711,"PHASE3":2724,"PHASE4":2726,"NA":2728},{"trials":2699,"activeCount":74},[],{"trials":2701,"activeCount":74},[2702],{"nctId":2703,"briefTitle":2704,"status":543,"phases":2705,"primaryCompletion":2706,"completion":2706,"start":2707,"enrollment":2708,"conditions":2709,"interventions":2710},"NCT06511791","An Exploratory Study to Investigate the Effect of FE 999302 When Given Together With Follitropin Delta at Different Time Intervals During Controlled Ovarian Stimulation.",[63],"2025-10-16","2024-07-15",106,[16],[2696,366],{"trials":2712,"activeCount":74},[2713],{"nctId":2714,"briefTitle":2715,"status":114,"phases":2716,"primaryCompletion":2717,"completion":2718,"start":2719,"enrollment":74,"conditions":2720,"interventions":2721},"NCT05571111","Clinical Research Study to Learn About the Effect and Safety of Different Doses of FE 999302 When Given as a Single Dose for Final Development of the Eggs After Ovarian Stimulation",[64],"2024-03-25","2024-06-25","2022-10-04",[16],[2696,2722,2723],"Ovitrelle","Novarel",{"trials":2725,"activeCount":74},[],{"trials":2727,"activeCount":74},[],{"trials":2729,"activeCount":74},[],{"intervention":2731,"totalTrials":108,"cells":2732},"Quinagolide 1080 µg",{"EARLY_PHASE1":2733,"PHASE1":2735,"PHASE2":2737,"PHASE3":2762,"PHASE4":2764,"NA":2766},{"trials":2734,"activeCount":74},[],{"trials":2736,"activeCount":74},[],{"trials":2738,"activeCount":74},[2739,2751],{"nctId":2740,"briefTitle":2741,"status":254,"phases":2742,"primaryCompletion":2743,"completion":2743,"start":2744,"enrollment":2745,"conditions":2746,"interventions":2748},"NCT03692403","Randomized Trial Assessing Quinagolide Vaginal Ring for Endometriosis-related Pain",[64],"2022-02-14","2018-12-26",22,[2747],"Endometriosis-related Pain",[2749,2750,2731],"Quinagolide 360 µg","Quinagolide 720 µg",{"nctId":2752,"briefTitle":2753,"status":254,"phases":2754,"primaryCompletion":2755,"completion":2756,"start":2757,"enrollment":2758,"conditions":2759,"interventions":2761},"NCT03749109","Quinagolide Vaginal Ring on Lesion Reduction Assessed by MRI in Women With Endometriosis\u002FAdenomyosis",[64],"2021-06-21","2021-07-18","2019-08-19",67,[2760],"Endometriosis",[2731],{"trials":2763,"activeCount":74},[],{"trials":2765,"activeCount":74},[],{"trials":2767,"activeCount":74},[],{"intervention":1220,"totalTrials":87,"cells":2769},{"EARLY_PHASE1":2770,"PHASE1":2772,"PHASE2":2774,"PHASE3":2780,"PHASE4":2782,"NA":2784},{"trials":2771,"activeCount":74},[],{"trials":2773,"activeCount":74},[],{"trials":2775,"activeCount":74},[2776],{"nctId":1213,"briefTitle":1214,"status":254,"phases":2777,"primaryCompletion":1181,"completion":439,"start":1216,"enrollment":1217,"conditions":2778,"interventions":2779},[64],[16],[1220,1220,1220,1204],{"trials":2781,"activeCount":74},[],{"trials":2783,"activeCount":74},[],{"trials":2785,"activeCount":74},[],{"intervention":2787,"totalTrials":87,"cells":2788},"A: Desmopressin 25 µg",{"EARLY_PHASE1":2789,"PHASE1":2791,"PHASE2":2793,"PHASE3":2804,"PHASE4":2806,"NA":2808},{"trials":2790,"activeCount":74},[],{"trials":2792,"activeCount":74},[],{"trials":2794,"activeCount":74},[2795],{"nctId":2796,"briefTitle":2797,"status":254,"phases":2798,"primaryCompletion":771,"completion":771,"start":2799,"enrollment":2800,"conditions":2801,"interventions":2802},"NCT01694498","Comparative Trial to Investigate the Efficacy and Safety of Desmopressin for the Treatment of Nocturia in Adult Men",[64],"2012-09",183,[19],[2787,2803],"B. Desmopressin 50 µg",{"trials":2805,"activeCount":74},[],{"trials":2807,"activeCount":74},[],{"trials":2809,"activeCount":74},[],{"intervention":2803,"totalTrials":87,"cells":2811},{"EARLY_PHASE1":2812,"PHASE1":2814,"PHASE2":2816,"PHASE3":2822,"PHASE4":2824,"NA":2826},{"trials":2813,"activeCount":74},[],{"trials":2815,"activeCount":74},[],{"trials":2817,"activeCount":74},[2818],{"nctId":2796,"briefTitle":2797,"status":254,"phases":2819,"primaryCompletion":771,"completion":771,"start":2799,"enrollment":2800,"conditions":2820,"interventions":2821},[64],[19],[2787,2803],{"trials":2823,"activeCount":74},[],{"trials":2825,"activeCount":74},[],{"trials":2827,"activeCount":74},[],{"intervention":2722,"totalTrials":87,"cells":2829},{"EARLY_PHASE1":2830,"PHASE1":2832,"PHASE2":2834,"PHASE3":2840,"PHASE4":2842,"NA":2844},{"trials":2831,"activeCount":74},[],{"trials":2833,"activeCount":74},[],{"trials":2835,"activeCount":74},[2836],{"nctId":2714,"briefTitle":2715,"status":114,"phases":2837,"primaryCompletion":2717,"completion":2718,"start":2719,"enrollment":74,"conditions":2838,"interventions":2839},[64],[16],[2696,2722,2723],{"trials":2841,"activeCount":74},[],{"trials":2843,"activeCount":74},[],{"trials":2845,"activeCount":74},[],{"intervention":2723,"totalTrials":87,"cells":2847},{"EARLY_PHASE1":2848,"PHASE1":2850,"PHASE2":2852,"PHASE3":2858,"PHASE4":2860,"NA":2862},{"trials":2849,"activeCount":74},[],{"trials":2851,"activeCount":74},[],{"trials":2853,"activeCount":74},[2854],{"nctId":2714,"briefTitle":2715,"status":114,"phases":2855,"primaryCompletion":2717,"completion":2718,"start":2719,"enrollment":74,"conditions":2856,"interventions":2857},[64],[16],[2696,2722,2723],{"trials":2859,"activeCount":74},[],{"trials":2861,"activeCount":74},[],{"trials":2863,"activeCount":74},[],{"intervention":2865,"totalTrials":87,"cells":2866},"FE 999302 (1 μg) and follitropin delta",{"EARLY_PHASE1":2867,"PHASE1":2869,"PHASE2":2871,"PHASE3":2886,"PHASE4":2888,"NA":2890},{"trials":2868,"activeCount":74},[],{"trials":2870,"activeCount":74},[],{"trials":2872,"activeCount":74},[2873],{"nctId":2874,"briefTitle":2875,"status":254,"phases":2876,"primaryCompletion":2877,"completion":2878,"start":2879,"enrollment":586,"conditions":2880,"interventions":2881},"NCT03564509","A Trial to Investigate the Efficacy and Safety of FE 999302 as add-on Treatment to Follitropin Delta (REKOVELLE) in Women Undergoing Controlled Ovarian Stimulation.",[64],"2019-10-21","2020-01-08","2018-05-14",[32],[2865,2882,2883,2884,2885],"FE 999302 (2 μg) and follitropin delta","FE 999302 (4 μg) and follitropin delta","FE 999302 (8 μg) and follitropin delta","FE 999302 (12 μg) and follitropin delta",{"trials":2887,"activeCount":74},[],{"trials":2889,"activeCount":74},[],{"trials":2891,"activeCount":74},[],{"intervention":2882,"totalTrials":87,"cells":2893},{"EARLY_PHASE1":2894,"PHASE1":2896,"PHASE2":2898,"PHASE3":2904,"PHASE4":2906,"NA":2908},{"trials":2895,"activeCount":74},[],{"trials":2897,"activeCount":74},[],{"trials":2899,"activeCount":74},[2900],{"nctId":2874,"briefTitle":2875,"status":254,"phases":2901,"primaryCompletion":2877,"completion":2878,"start":2879,"enrollment":586,"conditions":2902,"interventions":2903},[64],[32],[2865,2882,2883,2884,2885],{"trials":2905,"activeCount":74},[],{"trials":2907,"activeCount":74},[],{"trials":2909,"activeCount":74},[],{"intervention":2883,"totalTrials":87,"cells":2911},{"EARLY_PHASE1":2912,"PHASE1":2914,"PHASE2":2916,"PHASE3":2922,"PHASE4":2924,"NA":2926},{"trials":2913,"activeCount":74},[],{"trials":2915,"activeCount":74},[],{"trials":2917,"activeCount":74},[2918],{"nctId":2874,"briefTitle":2875,"status":254,"phases":2919,"primaryCompletion":2877,"completion":2878,"start":2879,"enrollment":586,"conditions":2920,"interventions":2921},[64],[32],[2865,2882,2883,2884,2885],{"trials":2923,"activeCount":74},[],{"trials":2925,"activeCount":74},[],{"trials":2927,"activeCount":74},[],{"intervention":2884,"totalTrials":87,"cells":2929},{"EARLY_PHASE1":2930,"PHASE1":2932,"PHASE2":2934,"PHASE3":2940,"PHASE4":2942,"NA":2944},{"trials":2931,"activeCount":74},[],{"trials":2933,"activeCount":74},[],{"trials":2935,"activeCount":74},[2936],{"nctId":2874,"briefTitle":2875,"status":254,"phases":2937,"primaryCompletion":2877,"completion":2878,"start":2879,"enrollment":586,"conditions":2938,"interventions":2939},[64],[32],[2865,2882,2883,2884,2885],{"trials":2941,"activeCount":74},[],{"trials":2943,"activeCount":74},[],{"trials":2945,"activeCount":74},[],{"intervention":2885,"totalTrials":87,"cells":2947},{"EARLY_PHASE1":2948,"PHASE1":2950,"PHASE2":2952,"PHASE3":2958,"PHASE4":2960,"NA":2962},{"trials":2949,"activeCount":74},[],{"trials":2951,"activeCount":74},[],{"trials":2953,"activeCount":74},[2954],{"nctId":2874,"briefTitle":2875,"status":254,"phases":2955,"primaryCompletion":2877,"completion":2878,"start":2879,"enrollment":586,"conditions":2956,"interventions":2957},[64],[32],[2865,2882,2883,2884,2885],{"trials":2959,"activeCount":74},[],{"trials":2961,"activeCount":74},[],{"trials":2963,"activeCount":74},[],{"intervention":1062,"totalTrials":87,"cells":2965},{"EARLY_PHASE1":2966,"PHASE1":2968,"PHASE2":2970,"PHASE3":2976,"PHASE4":2978,"NA":2980},{"trials":2967,"activeCount":74},[],{"trials":2969,"activeCount":74},[],{"trials":2971,"activeCount":74},[2972],{"nctId":1054,"briefTitle":1055,"status":254,"phases":2973,"primaryCompletion":1057,"completion":1058,"start":1012,"enrollment":1059,"conditions":2974,"interventions":2975},[64],[16],[418,1062],{"trials":2977,"activeCount":74},[],{"trials":2979,"activeCount":74},[],{"trials":2981,"activeCount":74},[],{"intervention":2983,"totalTrials":87,"cells":2984},"FE200440",{"EARLY_PHASE1":2985,"PHASE1":2987,"PHASE2":2989,"PHASE3":3002,"PHASE4":3004,"NA":3006},{"trials":2986,"activeCount":74},[],{"trials":2988,"activeCount":74},[],{"trials":2990,"activeCount":74},[2991],{"nctId":2992,"briefTitle":2993,"status":254,"phases":2994,"primaryCompletion":2011,"completion":2995,"start":2996,"enrollment":2997,"conditions":2998,"interventions":3001},"NCT00209326","A Proof of Concept Study Assessing the Effect of Four Different Single Bolus Intravenous Doses of FE200440 and Placebo on Stopping Preterm Labor",[64],"2006-08","2003-11",163,[2999,3000],"Labor, Premature","Premature Birth",[2983],{"trials":3003,"activeCount":74},[],{"trials":3005,"activeCount":74},[],{"trials":3007,"activeCount":74},[],{"intervention":2670,"totalTrials":87,"cells":3009},{"EARLY_PHASE1":3010,"PHASE1":3012,"PHASE2":3014,"PHASE3":3020,"PHASE4":3022,"NA":3024},{"trials":3011,"activeCount":74},[],{"trials":3013,"activeCount":74},[],{"trials":3015,"activeCount":74},[3016],{"nctId":2661,"briefTitle":2662,"status":254,"phases":3017,"primaryCompletion":297,"completion":2664,"start":2665,"enrollment":2666,"conditions":3018,"interventions":3019},[64],[2668],[2652,2670],{"trials":3021,"activeCount":74},[],{"trials":3023,"activeCount":74},[],{"trials":3025,"activeCount":74},[],{"intervention":1407,"totalTrials":87,"cells":3027},{"EARLY_PHASE1":3028,"PHASE1":3030,"PHASE2":3032,"PHASE3":3038,"PHASE4":3040,"NA":3042},{"trials":3029,"activeCount":74},[],{"trials":3031,"activeCount":74},[],{"trials":3033,"activeCount":74},[3034],{"nctId":1398,"briefTitle":1399,"status":254,"phases":3035,"primaryCompletion":1401,"completion":1402,"start":1403,"enrollment":772,"conditions":3036,"interventions":3037},[64],[1405,25],[1407,1389,1408,1409],{"trials":3039,"activeCount":74},[],{"trials":3041,"activeCount":74},[],{"trials":3043,"activeCount":74},[],{"intervention":1409,"totalTrials":87,"cells":3045},{"EARLY_PHASE1":3046,"PHASE1":3048,"PHASE2":3050,"PHASE3":3056,"PHASE4":3058,"NA":3060},{"trials":3047,"activeCount":74},[],{"trials":3049,"activeCount":74},[],{"trials":3051,"activeCount":74},[3052],{"nctId":1398,"briefTitle":1399,"status":254,"phases":3053,"primaryCompletion":1401,"completion":1402,"start":1403,"enrollment":772,"conditions":3054,"interventions":3055},[64],[1405,25],[1407,1389,1408,1409],{"trials":3057,"activeCount":74},[],{"trials":3059,"activeCount":74},[],{"trials":3061,"activeCount":74},[],{"intervention":3063,"totalTrials":87,"cells":3064},"Misoprostol Vaginal Insert",{"EARLY_PHASE1":3065,"PHASE1":3067,"PHASE2":3069,"PHASE3":3077,"PHASE4":3079,"NA":3081},{"trials":3066,"activeCount":74},[],{"trials":3068,"activeCount":74},[],{"trials":3070,"activeCount":74},[3071],{"nctId":3072,"briefTitle":3073,"status":114,"phases":3074,"enrollment":74,"conditions":3075,"interventions":3076},"NCT00528255","Pharmacokinetics and Safety of the 100 Mcg Misoprostol Vaginal Insert (MVI 100)",[64],[25,1175],[3063],{"trials":3078,"activeCount":74},[],{"trials":3080,"activeCount":74},[],{"trials":3082,"activeCount":74},[],{"intervention":3084,"totalTrials":87,"cells":3085},"FE 992097",{"EARLY_PHASE1":3086,"PHASE1":3088,"PHASE2":3090,"PHASE3":3102,"PHASE4":3104,"NA":3106},{"trials":3087,"activeCount":74},[],{"trials":3089,"activeCount":74},[],{"trials":3091,"activeCount":74},[3092],{"nctId":3093,"briefTitle":3094,"status":254,"phases":3095,"primaryCompletion":3096,"completion":3096,"start":3097,"enrollment":3098,"conditions":3099,"interventions":3101},"NCT01968187","Treatment of Hyperphagia Behavioral Symptoms in Children and Adults Diagnosed With Prader-Willi Syndrome",[64],"2014-07-16","2014-01-20",38,[3100],"Hyperphagia in Prader-Willi Syndrome",[3084],{"trials":3103,"activeCount":74},[],{"trials":3105,"activeCount":74},[],{"trials":3107,"activeCount":74},[],{"intervention":3109,"totalTrials":87,"cells":3110},"Terlipressin",{"EARLY_PHASE1":3111,"PHASE1":3113,"PHASE2":3115,"PHASE3":3125,"PHASE4":3127,"NA":3129},{"trials":3112,"activeCount":74},[],{"trials":3114,"activeCount":74},[],{"trials":3116,"activeCount":74},[3117],{"nctId":3118,"briefTitle":3119,"status":254,"phases":3120,"primaryCompletion":3121,"completion":1181,"start":2665,"enrollment":8,"conditions":3122,"interventions":3124},"NCT01373606","A Study of Terlipressin in Patients With Hepatorenal Syndrome Type 1",[63,64],"2009-03",[3123],"Hepatorenal Syndrome Type 1",[3109],{"trials":3126,"activeCount":74},[],{"trials":3128,"activeCount":74},[],{"trials":3130,"activeCount":74},[],{"intervention":3132,"totalTrials":87,"cells":3133},"Degarelix mid-luteal, 2.5 mg",{"EARLY_PHASE1":3134,"PHASE1":3136,"PHASE2":3138,"PHASE3":3147,"PHASE4":3149,"NA":3151},{"trials":3135,"activeCount":74},[],{"trials":3137,"activeCount":74},[],{"trials":3139,"activeCount":74},[3140],{"nctId":3141,"briefTitle":3142,"status":254,"phases":3143,"primaryCompletion":2486,"completion":2486,"start":2162,"enrollment":3144,"conditions":3145,"interventions":3146},"NCT00434122","Exploratory Study Assessing Synchronisation of Egg Sacs With Degarelix",[64],85,[28],[3132],{"trials":3148,"activeCount":74},[],{"trials":3150,"activeCount":74},[],{"trials":3152,"activeCount":74},[],{"intervention":3154,"totalTrials":87,"cells":3155},"Merotocin",{"EARLY_PHASE1":3156,"PHASE1":3158,"PHASE2":3160,"PHASE3":3171,"PHASE4":3173,"NA":3175},{"trials":3157,"activeCount":74},[],{"trials":3159,"activeCount":74},[],{"trials":3161,"activeCount":74},[3162],{"nctId":3163,"briefTitle":3164,"status":543,"phases":3165,"primaryCompletion":3166,"completion":3166,"start":2242,"enrollment":70,"conditions":3167,"interventions":3170},"NCT02545127","Merotocin in Mothers With Inadequate Milk Production and Infants Delivered Prematurely",[64],"2022-11-11",[3168,3169],"Preterm Delivery","Inadequate Milk Production",[3154],{"trials":3172,"activeCount":74},[],{"trials":3174,"activeCount":74},[],{"trials":3176,"activeCount":74},[],{"intervention":3178,"totalTrials":87,"cells":3179},"Degarelix 10 mg",{"EARLY_PHASE1":3180,"PHASE1":3182,"PHASE2":3184,"PHASE3":3197,"PHASE4":3199,"NA":3201},{"trials":3181,"activeCount":74},[],{"trials":3183,"activeCount":74},[],{"trials":3185,"activeCount":74},[3186],{"nctId":3187,"briefTitle":3188,"status":254,"phases":3189,"primaryCompletion":1022,"completion":3190,"start":1023,"enrollment":3191,"conditions":3192,"interventions":3194},"NCT00947882","A Trial of Degarelix in Men With Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH)",[64],"2011-06",404,[3193],"Lower Urinary Tract Symptoms (LUTS)",[3178,3195,3196],"Degarelix 20 mg","Degarelix 30 mg",{"trials":3198,"activeCount":74},[],{"trials":3200,"activeCount":74},[],{"trials":3202,"activeCount":74},[],{"intervention":3195,"totalTrials":87,"cells":3204},{"EARLY_PHASE1":3205,"PHASE1":3207,"PHASE2":3209,"PHASE3":3215,"PHASE4":3217,"NA":3219},{"trials":3206,"activeCount":74},[],{"trials":3208,"activeCount":74},[],{"trials":3210,"activeCount":74},[3211],{"nctId":3187,"briefTitle":3188,"status":254,"phases":3212,"primaryCompletion":1022,"completion":3190,"start":1023,"enrollment":3191,"conditions":3213,"interventions":3214},[64],[3193],[3178,3195,3196],{"trials":3216,"activeCount":74},[],{"trials":3218,"activeCount":74},[],{"trials":3220,"activeCount":74},[],{"intervention":3196,"totalTrials":87,"cells":3222},{"EARLY_PHASE1":3223,"PHASE1":3225,"PHASE2":3227,"PHASE3":3233,"PHASE4":3235,"NA":3237},{"trials":3224,"activeCount":74},[],{"trials":3226,"activeCount":74},[],{"trials":3228,"activeCount":74},[3229],{"nctId":3187,"briefTitle":3188,"status":254,"phases":3230,"primaryCompletion":1022,"completion":3190,"start":1023,"enrollment":3191,"conditions":3231,"interventions":3232},[64],[3193],[3178,3195,3196],{"trials":3234,"activeCount":74},[],{"trials":3236,"activeCount":74},[],{"trials":3238,"activeCount":74},[],{"intervention":3240,"totalTrials":87,"cells":3241},"FE 202158",{"EARLY_PHASE1":3242,"PHASE1":3244,"PHASE2":3246,"PHASE3":3256,"PHASE4":3258,"NA":3260},{"trials":3243,"activeCount":74},[],{"trials":3245,"activeCount":74},[],{"trials":3247,"activeCount":74},[3248],{"nctId":3249,"briefTitle":3250,"status":254,"phases":3251,"primaryCompletion":3252,"completion":3252,"start":1860,"enrollment":3253,"conditions":3254,"interventions":3255},"NCT01612676","Investigating FE 202158 as Potential Primary Treatment in Patients With Early Septic Shock",[64],"2013-11",31,[2382],[3240],{"trials":3257,"activeCount":74},[],{"trials":3259,"activeCount":74},[],{"trials":3261,"activeCount":74},[],{"intervention":3263,"totalTrials":87,"cells":3264},"elobixibat",{"EARLY_PHASE1":3265,"PHASE1":3267,"PHASE2":3269,"PHASE3":3277,"PHASE4":3279,"NA":3281},{"trials":3266,"activeCount":74},[],{"trials":3268,"activeCount":74},[],{"trials":3270,"activeCount":74},[3271],{"nctId":3272,"briefTitle":3273,"status":114,"phases":3274,"primaryCompletion":1818,"completion":1818,"start":1543,"enrollment":74,"conditions":3275,"interventions":3276},"NCT02392546","Elobixibat Colonic Motor Function Study",[64],[1591],[3263],{"trials":3278,"activeCount":74},[],{"trials":3280,"activeCount":74},[],{"trials":3282,"activeCount":74},[],{"intervention":2749,"totalTrials":87,"cells":3284},{"EARLY_PHASE1":3285,"PHASE1":3287,"PHASE2":3289,"PHASE3":3295,"PHASE4":3297,"NA":3299},{"trials":3286,"activeCount":74},[],{"trials":3288,"activeCount":74},[],{"trials":3290,"activeCount":74},[3291],{"nctId":2740,"briefTitle":2741,"status":254,"phases":3292,"primaryCompletion":2743,"completion":2743,"start":2744,"enrollment":2745,"conditions":3293,"interventions":3294},[64],[2747],[2749,2750,2731],{"trials":3296,"activeCount":74},[],{"trials":3298,"activeCount":74},[],{"trials":3300,"activeCount":74},[],{"intervention":2750,"totalTrials":87,"cells":3302},{"EARLY_PHASE1":3303,"PHASE1":3305,"PHASE2":3307,"PHASE3":3313,"PHASE4":3315,"NA":3317},{"trials":3304,"activeCount":74},[],{"trials":3306,"activeCount":74},[],{"trials":3308,"activeCount":74},[3309],{"nctId":2740,"briefTitle":2741,"status":254,"phases":3310,"primaryCompletion":2743,"completion":2743,"start":2744,"enrollment":2745,"conditions":3311,"interventions":3312},[64],[2747],[2749,2750,2731],{"trials":3314,"activeCount":74},[],{"trials":3316,"activeCount":74},[],{"trials":3318,"activeCount":74},[],{"intervention":3320,"totalTrials":87,"cells":3321},"FE 201836",{"EARLY_PHASE1":3322,"PHASE1":3324,"PHASE2":3326,"PHASE3":3337,"PHASE4":3339,"NA":3341},{"trials":3323,"activeCount":74},[],{"trials":3325,"activeCount":74},[],{"trials":3327,"activeCount":74},[3328],{"nctId":3329,"briefTitle":3330,"status":254,"phases":3331,"primaryCompletion":3332,"completion":3332,"start":3333,"enrollment":258,"conditions":3334,"interventions":3335},"NCT03201419","A Trial to Investigate Efficacy, Safety and Tolerability of FE 201836 for Nocturia Due to Nocturnal Polyuria in Adults",[64],"2019-10-31","2017-07-27",[19],[3320,3336],"Desmopressin",{"trials":3338,"activeCount":74},[],{"trials":3340,"activeCount":74},[],{"trials":3342,"activeCount":74},[],{"intervention":3344,"totalTrials":87,"cells":3345},"Prepopik® ½ Sachet x 2",{"EARLY_PHASE1":3346,"PHASE1":3348,"PHASE2":3350,"PHASE3":3365,"PHASE4":3367,"NA":3369},{"trials":3347,"activeCount":74},[],{"trials":3349,"activeCount":74},[],{"trials":3351,"activeCount":74},[3352],{"nctId":3353,"briefTitle":3354,"status":254,"phases":3355,"primaryCompletion":3356,"completion":3357,"start":3358,"enrollment":3359,"conditions":3360,"interventions":3362},"NCT01928862","Efficacy and Safety of Prepopik® in Children for Overall Colon Cleansing in Preparation for Colonoscopy",[63,64],"2017-02-15","2017-03-16","2014-06-03",78,[3361],"Need for Bowel Preparation",[3344,3363,3364,3363,3364],"Prepopik® 1 Sachet x 2","Oral polyethylene glycol",{"trials":3366,"activeCount":74},[],{"trials":3368,"activeCount":74},[],{"trials":3370,"activeCount":74},[],{"intervention":3363,"totalTrials":87,"cells":3372},{"EARLY_PHASE1":3373,"PHASE1":3375,"PHASE2":3377,"PHASE3":3383,"PHASE4":3385,"NA":3387},{"trials":3374,"activeCount":74},[],{"trials":3376,"activeCount":74},[],{"trials":3378,"activeCount":74},[3379],{"nctId":3353,"briefTitle":3354,"status":254,"phases":3380,"primaryCompletion":3356,"completion":3357,"start":3358,"enrollment":3359,"conditions":3381,"interventions":3382},[63,64],[3361],[3344,3363,3364,3363,3364],{"trials":3384,"activeCount":74},[],{"trials":3386,"activeCount":74},[],{"trials":3388,"activeCount":74},[],{"intervention":3364,"totalTrials":87,"cells":3390},{"EARLY_PHASE1":3391,"PHASE1":3393,"PHASE2":3395,"PHASE3":3401,"PHASE4":3403,"NA":3405},{"trials":3392,"activeCount":74},[],{"trials":3394,"activeCount":74},[],{"trials":3396,"activeCount":74},[3397],{"nctId":3353,"briefTitle":3354,"status":254,"phases":3398,"primaryCompletion":3356,"completion":3357,"start":3358,"enrollment":3359,"conditions":3399,"interventions":3400},[63,64],[3361],[3344,3363,3364,3363,3364],{"trials":3402,"activeCount":74},[],{"trials":3404,"activeCount":74},[],{"trials":3406,"activeCount":74},[],{"intervention":1289,"totalTrials":87,"cells":3408},{"EARLY_PHASE1":3409,"PHASE1":3411,"PHASE2":3413,"PHASE3":3419,"PHASE4":3421,"NA":3423},{"trials":3410,"activeCount":74},[],{"trials":3412,"activeCount":74},[],{"trials":3414,"activeCount":74},[3415],{"nctId":1281,"briefTitle":1282,"status":254,"phases":3416,"primaryCompletion":452,"completion":452,"start":1284,"enrollment":1285,"conditions":3417,"interventions":3418},[64],[1287],[1289,1272],{"trials":3420,"activeCount":74},[],{"trials":3422,"activeCount":74},[],{"trials":3424,"activeCount":74},[],{"intervention":1185,"totalTrials":87,"cells":3426},{"EARLY_PHASE1":3427,"PHASE1":3429,"PHASE2":3431,"PHASE3":3437,"PHASE4":3439,"NA":3441},{"trials":3428,"activeCount":74},[],{"trials":3430,"activeCount":74},[],{"trials":3432,"activeCount":74},[3433],{"nctId":1178,"briefTitle":1179,"status":254,"phases":3434,"primaryCompletion":1181,"completion":1181,"start":391,"enrollment":1182,"conditions":3435,"interventions":3436},[64],[25,1175],[1185,1186,1161],{"trials":3438,"activeCount":74},[],{"trials":3440,"activeCount":74},[],{"trials":3442,"activeCount":74},[],{"intervention":1186,"totalTrials":87,"cells":3444},{"EARLY_PHASE1":3445,"PHASE1":3447,"PHASE2":3449,"PHASE3":3455,"PHASE4":3457,"NA":3459},{"trials":3446,"activeCount":74},[],{"trials":3448,"activeCount":74},[],{"trials":3450,"activeCount":74},[3451],{"nctId":1178,"briefTitle":1179,"status":254,"phases":3452,"primaryCompletion":1181,"completion":1181,"start":391,"enrollment":1182,"conditions":3453,"interventions":3454},[64],[25,1175],[1185,1186,1161],{"trials":3456,"activeCount":74},[],{"trials":3458,"activeCount":74},[],{"trials":3460,"activeCount":74},[],{"intervention":3462,"totalTrials":87,"cells":3463},"FE 202158 1.25",{"EARLY_PHASE1":3464,"PHASE1":3466,"PHASE2":3468,"PHASE3":3479,"PHASE4":3481,"NA":3483},{"trials":3465,"activeCount":74},[],{"trials":3467,"activeCount":74},[],{"trials":3469,"activeCount":74},[3470],{"nctId":3471,"briefTitle":3472,"status":254,"phases":3473,"primaryCompletion":2097,"completion":1012,"start":438,"enrollment":3474,"conditions":3475,"interventions":3476},"NCT01000649","Effects of the V1a Agonist FE 202158 in Patients With Septic Shock",[64],53,[2382],[3462,3477,3478],"FE 202158 2.5","FE 202158 3.75",{"trials":3480,"activeCount":74},[],{"trials":3482,"activeCount":74},[],{"trials":3484,"activeCount":74},[],{"intervention":3477,"totalTrials":87,"cells":3486},{"EARLY_PHASE1":3487,"PHASE1":3489,"PHASE2":3491,"PHASE3":3497,"PHASE4":3499,"NA":3501},{"trials":3488,"activeCount":74},[],{"trials":3490,"activeCount":74},[],{"trials":3492,"activeCount":74},[3493],{"nctId":3471,"briefTitle":3472,"status":254,"phases":3494,"primaryCompletion":2097,"completion":1012,"start":438,"enrollment":3474,"conditions":3495,"interventions":3496},[64],[2382],[3462,3477,3478],{"trials":3498,"activeCount":74},[],{"trials":3500,"activeCount":74},[],{"trials":3502,"activeCount":74},[],{"intervention":3478,"totalTrials":87,"cells":3504},{"EARLY_PHASE1":3505,"PHASE1":3507,"PHASE2":3509,"PHASE3":3515,"PHASE4":3517,"NA":3519},{"trials":3506,"activeCount":74},[],{"trials":3508,"activeCount":74},[],{"trials":3510,"activeCount":74},[3511],{"nctId":3471,"briefTitle":3472,"status":254,"phases":3512,"primaryCompletion":2097,"completion":1012,"start":438,"enrollment":3474,"conditions":3513,"interventions":3514},[64],[2382],[3462,3477,3478],{"trials":3516,"activeCount":74},[],{"trials":3518,"activeCount":74},[],{"trials":3520,"activeCount":74},[],{"intervention":3522,"totalTrials":87,"cells":3523},"A. Desmopressin 10 microgram",{"EARLY_PHASE1":3524,"PHASE1":3526,"PHASE2":3528,"PHASE3":3539,"PHASE4":3541,"NA":3543},{"trials":3525,"activeCount":74},[],{"trials":3527,"activeCount":74},[],{"trials":3529,"activeCount":74},[3530],{"nctId":3531,"briefTitle":3532,"status":254,"phases":3533,"primaryCompletion":771,"completion":771,"start":2799,"enrollment":3534,"conditions":3535,"interventions":3536},"NCT01684800","Comparative Trial to Investigate the Efficacy and Safety of Desmopressin for the Treatment of Nocturia in Adult Women",[64],178,[19],[3522,3537,3538],"B: Desmopressin 25 microgram","C: Placebo",{"trials":3540,"activeCount":74},[],{"trials":3542,"activeCount":74},[],{"trials":3544,"activeCount":74},[],{"intervention":3537,"totalTrials":87,"cells":3546},{"EARLY_PHASE1":3547,"PHASE1":3549,"PHASE2":3551,"PHASE3":3557,"PHASE4":3559,"NA":3561},{"trials":3548,"activeCount":74},[],{"trials":3550,"activeCount":74},[],{"trials":3552,"activeCount":74},[3553],{"nctId":3531,"briefTitle":3532,"status":254,"phases":3554,"primaryCompletion":771,"completion":771,"start":2799,"enrollment":3534,"conditions":3555,"interventions":3556},[64],[19],[3522,3537,3538],{"trials":3558,"activeCount":74},[],{"trials":3560,"activeCount":74},[],{"trials":3562,"activeCount":74},[],{"intervention":3538,"totalTrials":87,"cells":3564},{"EARLY_PHASE1":3565,"PHASE1":3567,"PHASE2":3569,"PHASE3":3575,"PHASE4":3577,"NA":3579},{"trials":3566,"activeCount":74},[],{"trials":3568,"activeCount":74},[],{"trials":3570,"activeCount":74},[3571],{"nctId":3531,"briefTitle":3532,"status":254,"phases":3572,"primaryCompletion":771,"completion":771,"start":2799,"enrollment":3534,"conditions":3573,"interventions":3574},[64],[19],[3522,3537,3538],{"trials":3576,"activeCount":74},[],{"trials":3578,"activeCount":74},[],{"trials":3580,"activeCount":74},[],{"intervention":3582,"totalTrials":87,"cells":3583},"Norprolac",{"EARLY_PHASE1":3584,"PHASE1":3586,"PHASE2":3588,"PHASE3":3597,"PHASE4":3599,"NA":3601},{"trials":3585,"activeCount":74},[],{"trials":3587,"activeCount":74},[],{"trials":3589,"activeCount":74},[3590],{"nctId":3591,"briefTitle":3592,"status":254,"phases":3593,"primaryCompletion":1416,"completion":297,"start":2641,"enrollment":1024,"conditions":3594,"interventions":3596},"NCT00329693","Study Assessing the Effect of 3-week Treatment With One of Three Oral Doses of Quinagolide",[64],[3595],"Ovarian Hyperstimulation Syndrome",[3582,3582,3582,3582],{"trials":3598,"activeCount":74},[],{"trials":3600,"activeCount":74},[],{"trials":3602,"activeCount":74},[],{"intervention":3604,"totalTrials":87,"cells":3605},"Tolterodine tartrate extended release",{"EARLY_PHASE1":3606,"PHASE1":3608,"PHASE2":3610,"PHASE3":3620,"PHASE4":3622,"NA":3624},{"trials":3607,"activeCount":74},[],{"trials":3609,"activeCount":74},[],{"trials":3611,"activeCount":74},[3612],{"nctId":3613,"briefTitle":3614,"status":254,"phases":3615,"primaryCompletion":1125,"completion":1125,"start":770,"enrollment":2708,"conditions":3616,"interventions":3618},"NCT01729819","Interventional Clinical Trial in Patients in Overactive Bladder With Nocturia in Women",[64],[3617],"Overactive Bladder",[3604,3619],"Desmopressin orally disintegrating",{"trials":3621,"activeCount":74},[],{"trials":3623,"activeCount":74},[],{"trials":3625,"activeCount":74},[],{"intervention":3619,"totalTrials":87,"cells":3627},{"EARLY_PHASE1":3628,"PHASE1":3630,"PHASE2":3632,"PHASE3":3638,"PHASE4":3640,"NA":3642},{"trials":3629,"activeCount":74},[],{"trials":3631,"activeCount":74},[],{"trials":3633,"activeCount":74},[3634],{"nctId":3613,"briefTitle":3614,"status":254,"phases":3635,"primaryCompletion":1125,"completion":1125,"start":770,"enrollment":2708,"conditions":3636,"interventions":3637},[64],[3617],[3604,3619],{"trials":3639,"activeCount":74},[],{"trials":3641,"activeCount":74},[],{"trials":3643,"activeCount":74},[],{"intervention":3645,"totalTrials":87,"cells":3646},"Carbetocin",{"EARLY_PHASE1":3647,"PHASE1":3649,"PHASE2":3661,"PHASE3":3663,"PHASE4":3665,"NA":3667},{"trials":3648,"activeCount":74},[],{"trials":3650,"activeCount":74},[3651],{"nctId":3652,"briefTitle":3653,"status":254,"phases":3654,"primaryCompletion":3655,"completion":3655,"start":3656,"enrollment":3657,"conditions":3658,"interventions":3660},"NCT05924321","A Study to Evaluate the Effect of Carbetocin on the QT\u002FQTc Interval in Healthy Subjects",[63],"2023-09-21","2023-05-25",40,[3659],"Postpartum Hemorrhage",[3645],{"trials":3662,"activeCount":74},[],{"trials":3664,"activeCount":74},[],{"trials":3666,"activeCount":74},[],{"trials":3668,"activeCount":74},[],{"intervention":3670,"totalTrials":87,"cells":3671},"FE 204205",{"EARLY_PHASE1":3672,"PHASE1":3674,"PHASE2":3685,"PHASE3":3687,"PHASE4":3689,"NA":3691},{"trials":3673,"activeCount":74},[],{"trials":3675,"activeCount":74},[3676],{"nctId":3677,"briefTitle":3678,"status":543,"phases":3679,"primaryCompletion":3680,"completion":3680,"start":3681,"enrollment":70,"conditions":3682,"interventions":3684},"NCT02929407","A Study to Investigate the Safety and Effect of the Study Drug (FE 204205) in Patients With Cirrhotic Portal Hypertension",[63],"2017-09-27","2016-11",[3683],"Portal Hypertension",[3670],{"trials":3686,"activeCount":74},[],{"trials":3688,"activeCount":74},[],{"trials":3690,"activeCount":74},[],{"trials":3692,"activeCount":74},[],{"intervention":3694,"totalTrials":87,"cells":3695},"Microbiota suspension",{"EARLY_PHASE1":3696,"PHASE1":3698,"PHASE2":3709,"PHASE3":3711,"PHASE4":3713,"NA":3715},{"trials":3697,"activeCount":74},[],{"trials":3699,"activeCount":74},[3700],{"nctId":3701,"briefTitle":3702,"status":114,"phases":3703,"primaryCompletion":3704,"completion":3704,"start":3705,"enrollment":74,"conditions":3706,"interventions":3707},"NCT06260267","A Phase 1b Proof-of-concept Trial Exploring the Effects of FE 999322 and FE 999324 in Adults With Mild to Moderate Ulcerative Colitis",[63],"2026-01-15","2024-03-12",[22],[3694,3708],"Microbiota",{"trials":3710,"activeCount":74},[],{"trials":3712,"activeCount":74},[],{"trials":3714,"activeCount":74},[],{"trials":3716,"activeCount":74},[],{"intervention":3708,"totalTrials":87,"cells":3718},{"EARLY_PHASE1":3719,"PHASE1":3721,"PHASE2":3727,"PHASE3":3729,"PHASE4":3731,"NA":3733},{"trials":3720,"activeCount":74},[],{"trials":3722,"activeCount":74},[3723],{"nctId":3701,"briefTitle":3702,"status":114,"phases":3724,"primaryCompletion":3704,"completion":3704,"start":3705,"enrollment":74,"conditions":3725,"interventions":3726},[63],[22],[3694,3708],{"trials":3728,"activeCount":74},[],{"trials":3730,"activeCount":74},[],{"trials":3732,"activeCount":74},[],{"trials":3734,"activeCount":74},[],{"intervention":3736,"totalTrials":87,"cells":3737},"FE999302",{"EARLY_PHASE1":3738,"PHASE1":3740,"PHASE2":3752,"PHASE3":3754,"PHASE4":3756,"NA":3758},{"trials":3739,"activeCount":74},[],{"trials":3741,"activeCount":74},[3742],{"nctId":3743,"briefTitle":3744,"status":543,"phases":3745,"primaryCompletion":3746,"completion":3746,"start":3747,"enrollment":3748,"conditions":3749,"interventions":3750},"NCT06466486","An Exploratory Study to Investigate the Effect of FE 999302 When Given Together With Follitropin Delta During Controlled Ovarian Stimulation",[63],"2025-12-03","2024-06-14",310,[2015],[366,3736,3751],"FE999302 Placebo",{"trials":3753,"activeCount":74},[],{"trials":3755,"activeCount":74},[],{"trials":3757,"activeCount":74},[],{"trials":3759,"activeCount":74},[],{"intervention":3751,"totalTrials":87,"cells":3761},{"EARLY_PHASE1":3762,"PHASE1":3764,"PHASE2":3770,"PHASE3":3772,"PHASE4":3774,"NA":3776},{"trials":3763,"activeCount":74},[],{"trials":3765,"activeCount":74},[3766],{"nctId":3743,"briefTitle":3744,"status":543,"phases":3767,"primaryCompletion":3746,"completion":3746,"start":3747,"enrollment":3748,"conditions":3768,"interventions":3769},[63],[2015],[366,3736,3751],{"trials":3771,"activeCount":74},[],{"trials":3773,"activeCount":74},[],{"trials":3775,"activeCount":74},[],{"trials":3777,"activeCount":74},[],{"intervention":3779,"totalTrials":87,"cells":3780},"Lutrepulse",{"EARLY_PHASE1":3781,"PHASE1":3783,"PHASE2":3794,"PHASE3":3796,"PHASE4":3798,"NA":3800},{"trials":3782,"activeCount":74},[],{"trials":3784,"activeCount":74},[3785],{"nctId":3786,"briefTitle":3787,"status":114,"phases":3788,"primaryCompletion":3789,"completion":3789,"start":3790,"enrollment":74,"conditions":3791,"interventions":3793},"NCT07152730","A Study to Measure Pharmacokinetic (PK) Concentrations of Gonadotropin-Releasing Hormone Delivered by the OmniPod Pump",[63],"2025-10-29","2025-09-12",[3792,2015,16],"Amenorrhea",[3779],{"trials":3795,"activeCount":74},[],{"trials":3797,"activeCount":74},[],{"trials":3799,"activeCount":74},[],{"trials":3801,"activeCount":74},[],{"intervention":3803,"totalTrials":87,"cells":3804},"A MENOPUR solution for injection in pre-filled pen, 600 IU\u002F0.96 mL",{"EARLY_PHASE1":3805,"PHASE1":3807,"PHASE2":3819,"PHASE3":3821,"PHASE4":3823,"NA":3825},{"trials":3806,"activeCount":74},[],{"trials":3808,"activeCount":74},[3809],{"nctId":3810,"briefTitle":3811,"status":254,"phases":3812,"primaryCompletion":3813,"completion":3813,"start":3814,"enrollment":3815,"conditions":3816,"interventions":3817},"NCT04902131","A Study Comparing MENOPUR in a Pen Formulation With a Powder and Solvent Formulation in Healthy Women",[63],"2022-08-15","2021-11-02",95,[28],[3803,3818],"A MENOPUR powder including solvent for solution for injection, 75 IU",{"trials":3820,"activeCount":74},[],{"trials":3822,"activeCount":74},[],{"trials":3824,"activeCount":74},[],{"trials":3826,"activeCount":74},[],{"intervention":3818,"totalTrials":87,"cells":3828},{"EARLY_PHASE1":3829,"PHASE1":3831,"PHASE2":3837,"PHASE3":3839,"PHASE4":3841,"NA":3843},{"trials":3830,"activeCount":74},[],{"trials":3832,"activeCount":74},[3833],{"nctId":3810,"briefTitle":3811,"status":254,"phases":3834,"primaryCompletion":3813,"completion":3813,"start":3814,"enrollment":3815,"conditions":3835,"interventions":3836},[63],[28],[3803,3818],{"trials":3838,"activeCount":74},[],{"trials":3840,"activeCount":74},[],{"trials":3842,"activeCount":74},[],{"trials":3844,"activeCount":74},[],{"intervention":3846,"totalTrials":87,"cells":3847},"FE 999301",{"EARLY_PHASE1":3848,"PHASE1":3850,"PHASE2":3861,"PHASE3":3863,"PHASE4":3865,"NA":3867},{"trials":3849,"activeCount":74},[],{"trials":3851,"activeCount":74},[3852],{"nctId":3853,"briefTitle":3854,"status":254,"phases":3855,"primaryCompletion":3856,"completion":3856,"start":3857,"enrollment":1173,"conditions":3858,"interventions":3860},"NCT06515834","Investigating the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Olamkicept in Healthy Japanese Persons",[63],"2024-11-28","2024-07-01",[3859],"Gastroenterology",[3846],{"trials":3862,"activeCount":74},[],{"trials":3864,"activeCount":74},[],{"trials":3866,"activeCount":74},[],{"trials":3868,"activeCount":74},[],{"intervention":3870,"totalTrials":87,"cells":3871},"Olamkicept Part A",{"EARLY_PHASE1":3872,"PHASE1":3874,"PHASE2":3887,"PHASE3":3889,"PHASE4":3891,"NA":3893},{"trials":3873,"activeCount":74},[],{"trials":3875,"activeCount":74},[3876],{"nctId":3877,"briefTitle":3878,"status":254,"phases":3879,"primaryCompletion":3880,"completion":3880,"start":3881,"enrollment":3882,"conditions":3883,"interventions":3885},"NCT06298032","A Study Investigating the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Olamkicept in Healthy Persons",[63],"2024-11-15","2024-02-20",49,[3884],"Inflammatory Gastrointestinal Diseases",[3870,3886],"Olamkicept Part B",{"trials":3888,"activeCount":74},[],{"trials":3890,"activeCount":74},[],{"trials":3892,"activeCount":74},[],{"trials":3894,"activeCount":74},[],{"intervention":3886,"totalTrials":87,"cells":3896},{"EARLY_PHASE1":3897,"PHASE1":3899,"PHASE2":3905,"PHASE3":3907,"PHASE4":3909,"NA":3911},{"trials":3898,"activeCount":74},[],{"trials":3900,"activeCount":74},[3901],{"nctId":3877,"briefTitle":3878,"status":254,"phases":3902,"primaryCompletion":3880,"completion":3880,"start":3881,"enrollment":3882,"conditions":3903,"interventions":3904},[63],[3884],[3870,3886],{"trials":3906,"activeCount":74},[],{"trials":3908,"activeCount":74},[],{"trials":3910,"activeCount":74},[],{"trials":3912,"activeCount":74},[],{"intervention":3914,"totalTrials":87,"cells":3915},"CPSI-2364 or placebo",{"EARLY_PHASE1":3916,"PHASE1":3918,"PHASE2":3927,"PHASE3":3929,"PHASE4":3931,"NA":3933},{"trials":3917,"activeCount":74},[],{"trials":3919,"activeCount":74},[3920],{"nctId":3921,"briefTitle":3922,"status":254,"phases":3923,"primaryCompletion":3924,"completion":3924,"start":571,"enrollment":212,"conditions":3925,"interventions":3926},"NCT00950105","Single Ascending Dose Study of Oral CPSI-2364 (Semapimod)",[63],"2009-10",[30],[3914],{"trials":3928,"activeCount":74},[],{"trials":3930,"activeCount":74},[],{"trials":3932,"activeCount":74},[],{"trials":3934,"activeCount":74},[],{"intervention":1016,"totalTrials":3936,"cells":3937},37,{"EARLY_PHASE1":3938,"PHASE1":3940,"PHASE2":3951,"PHASE3":4053,"PHASE4":4157,"NA":4168},{"trials":3939,"activeCount":74},[],{"trials":3941,"activeCount":74},[3942],{"nctId":3943,"briefTitle":3944,"status":254,"phases":3945,"primaryCompletion":3946,"completion":3947,"start":1532,"enrollment":23,"conditions":3948,"interventions":3949},"NCT02468284","Pharmacokinetics of Degarelix in Chinese Patients With Prostate Cancer",[63],"2016-10-13","2017-10-10",[14],[3950],"degarelix",{"trials":3952,"activeCount":74},[3953,3960,3968,3977,3984,3990,3995,4002,4010,4019,4027,4035,4045],{"nctId":3954,"briefTitle":3955,"status":254,"phases":3956,"primaryCompletion":851,"completion":851,"start":1401,"enrollment":3957,"conditions":3958,"interventions":3959},"NCT00116779","A Parallel Group Comparison of the Efficacy and Safety of Degarelix at Two Different Dosing Regimens in Patients With Prostate Cancer",[64],127,[14],[1016],{"nctId":3961,"briefTitle":3962,"status":254,"phases":3963,"primaryCompletion":3964,"completion":3964,"start":1507,"enrollment":3965,"conditions":3966,"interventions":3967},"NCT00468286","Investigating Efficacy and Safety of Two Degarelix Three-Month Dosing Regimens in Patients With Prostate Cancer Requiring Androgen Ablation Therapy",[64],"2008-08",133,[14],[1016,1016],{"nctId":3969,"briefTitle":3970,"status":543,"phases":3971,"primaryCompletion":3972,"completion":3972,"start":3973,"enrollment":3974,"conditions":3975,"interventions":3976},"NCT00215657","Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients",[64],"2006-03","2003-03",131,[14],[1016,1016,1016,1016,1016,1016,1016,1016],{"nctId":3978,"briefTitle":3979,"status":254,"phases":3980,"primaryCompletion":2676,"completion":2676,"start":545,"enrollment":3981,"conditions":3982,"interventions":3983},"NCT01491971","Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate Cancer",[64],76,[14],[1016],{"nctId":3985,"briefTitle":3986,"status":254,"phases":3987,"primaryCompletion":958,"completion":958,"start":390,"enrollment":3936,"conditions":3988,"interventions":3989},"NCT00738673","Degarelix as Second-Line Hormonal Treatment After Prostate-specific Antigen (PSA)-Failure in GnRH Agonist Treated Patients With Prostate Cancer",[64],[14],[3950],{"nctId":3991,"briefTitle":3970,"status":543,"phases":3992,"primaryCompletion":1227,"completion":1227,"start":2633,"enrollment":3936,"conditions":3993,"interventions":3994},"NCT00117312",[64],[14],[1016,1016,1016,1016],{"nctId":3996,"briefTitle":3997,"status":254,"phases":3998,"primaryCompletion":307,"completion":631,"start":1401,"enrollment":3999,"conditions":4000,"interventions":4001},"NCT00819156","Dose Finding Trial With a New Treatment (Degarelix) for Prostate Cancer",[64],189,[14],[3950],{"nctId":4003,"briefTitle":4004,"status":254,"phases":4005,"primaryCompletion":3121,"completion":287,"start":2139,"enrollment":4006,"conditions":4007,"interventions":4009},"NCT00527488","Explorative Study of Degarelix for Treatment of Benign Prostatic Hyperplasia.",[64],52,[4008],"BPH",[1016,1016,1016,1016],{"nctId":4011,"briefTitle":4012,"status":254,"phases":4013,"primaryCompletion":4014,"completion":4014,"start":4015,"enrollment":4016,"conditions":4017,"interventions":4018},"NCT00818623","Investigation of a New Trial Drug (FE200486) in Prostate Cancer Patients",[64],"2004-10","2002-11",172,[14],[1016,1016,1016,1016,1016,1016,1016,1016],{"nctId":4020,"briefTitle":4021,"status":254,"phases":4022,"primaryCompletion":4023,"completion":4023,"start":632,"enrollment":4024,"conditions":4025,"interventions":4026},"NCT00117949","Study Investigating the Pharmacokinetics, Pharmacodynamics and Safety of FE200486",[64],"2004-01",82,[14],[1016,1016,1016,1016],{"nctId":4028,"briefTitle":4029,"status":254,"phases":4030,"primaryCompletion":298,"completion":298,"start":4031,"enrollment":4032,"conditions":4033,"interventions":4034},"NCT00116753","A Comparative Study of Degarelix Three-month Depot in Three Different Dosing Regimens in Patients With Prostate Cancer",[64],"2005-01",460,[14],[1016,1016,1016],{"nctId":4036,"briefTitle":4037,"status":254,"phases":4038,"primaryCompletion":4039,"completion":4040,"start":4041,"enrollment":4042,"conditions":4043,"interventions":4044},"NCT00819247","The Efficacy and Safety of FE 200486 in Treatment of Patients Suffering From Prostate Cancer",[64],"2002-05","2002-08","2001-03",129,[14],[1016],{"nctId":4046,"briefTitle":4047,"status":543,"phases":4048,"primaryCompletion":3972,"completion":3972,"start":4049,"enrollment":4050,"conditions":4051,"interventions":4052},"NCT00245466","Study Investigating the Long-Term Safety and Tolerability of Repeated Doses of Degarelix in Prostate Cancer Patients",[64],"2001-10",88,[14],[1016,1016,1016],{"trials":4054,"activeCount":74},[4055,4059,4065,4069,4073,4077,4084,4088,4097,4103,4107,4116,4122,4129,4133,4137,4145,4149],{"nctId":1009,"briefTitle":1010,"status":254,"phases":4056,"primaryCompletion":1012,"completion":1012,"start":391,"enrollment":1013,"conditions":4057,"interventions":4058},[65],[14],[1016,998,1017],{"nctId":4060,"briefTitle":4061,"status":114,"phases":4062,"enrollment":74,"conditions":4063,"interventions":4064},"NCT00728533","Open-Label, Randomised Parallel-Group Study",[65],[14],[1016,1016],{"nctId":1019,"briefTitle":1020,"status":254,"phases":4066,"primaryCompletion":1022,"completion":1022,"start":1023,"enrollment":1024,"conditions":4067,"interventions":4068},[65],[14],[1016,998,1017],{"nctId":1251,"briefTitle":1252,"status":254,"phases":4070,"primaryCompletion":1254,"completion":1254,"start":287,"enrollment":1255,"conditions":4071,"interventions":4072},[65],[14],[1016,1016,1240],{"nctId":1371,"briefTitle":1372,"status":543,"phases":4074,"primaryCompletion":958,"completion":545,"start":479,"enrollment":289,"conditions":4075,"interventions":4076},[65],[14],[1016,1360],{"nctId":4078,"briefTitle":4079,"status":254,"phases":4080,"primaryCompletion":3924,"completion":438,"start":1228,"enrollment":4081,"conditions":4082,"interventions":4083},"NCT00215683","An Extension Study Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Depots in Prostate Cancer",[64,65],137,[14],[1016],{"nctId":1377,"briefTitle":1378,"status":254,"phases":4085,"primaryCompletion":1022,"completion":1022,"start":1380,"enrollment":1381,"conditions":4086,"interventions":4087},[65],[14],[1016,1360],{"nctId":4089,"briefTitle":4090,"status":254,"phases":4091,"primaryCompletion":4092,"completion":1181,"start":4093,"enrollment":4094,"conditions":4095,"interventions":4096},"NCT00268892","Extension Study Investigating the Long-Term Safety of Degarelix Three-Month Depots in Patients With Prostate Cancer",[64,65],"2009-09","2006-01",278,[14],[1016,1016,1016],{"nctId":4098,"briefTitle":4099,"status":254,"phases":4100,"primaryCompletion":1645,"completion":1645,"start":2684,"enrollment":455,"conditions":4101,"interventions":4102},"NCT01220869","A Study of Degarelix in Taiwanese Patients With Prostate Cancer",[65],[14],[1016],{"nctId":1259,"briefTitle":1260,"status":543,"phases":4104,"primaryCompletion":1262,"completion":1262,"start":1263,"enrollment":1264,"conditions":4105,"interventions":4106},[65],[14],[1016,1240],{"nctId":4108,"briefTitle":4109,"status":254,"phases":4110,"primaryCompletion":4111,"completion":4112,"start":499,"enrollment":4113,"conditions":4114,"interventions":4115},"NCT02526784","A Trial Evaluating Two Subcutaneous Injection Techniques and Intramuscular Administration of Degarelix in Patients With Prostate Cancer",[65],"2017-05","2017-06",120,[14],[3950],{"nctId":4117,"briefTitle":4118,"status":254,"phases":4119,"primaryCompletion":1057,"completion":1057,"start":453,"enrollment":3957,"conditions":4120,"interventions":4121},"NCT01215513","Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Korean Patients",[65],[14],[1016],{"nctId":4123,"briefTitle":4124,"status":254,"phases":4125,"primaryCompletion":2462,"completion":958,"start":1023,"enrollment":4126,"conditions":4127,"interventions":4128},"NCT00967018","A Long Term Safety Study of Degarelix in Patients With Prostate Cancer",[65],77,[14],[1016],{"nctId":1028,"briefTitle":1029,"status":543,"phases":4130,"primaryCompletion":546,"completion":452,"start":391,"enrollment":1031,"conditions":4131,"interventions":4132},[65],[14],[1016,998,1017],{"nctId":2136,"briefTitle":2137,"status":254,"phases":4134,"primaryCompletion":2139,"completion":2139,"start":894,"enrollment":586,"conditions":4135,"interventions":4136},[65],[14],[1016,1016,2125],{"nctId":4138,"briefTitle":4139,"status":254,"phases":4140,"primaryCompletion":4092,"completion":438,"start":4141,"enrollment":4142,"conditions":4143,"interventions":4144},"NCT00117286","Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer",[64,65],"2005-03",57,[14],[1016],{"nctId":1035,"briefTitle":1036,"status":254,"phases":4146,"primaryCompletion":347,"completion":347,"start":770,"enrollment":1038,"conditions":4147,"interventions":4148},[65],[14],[1016,998],{"nctId":4150,"briefTitle":4151,"status":254,"phases":4152,"primaryCompletion":4153,"completion":4153,"start":4154,"enrollment":1884,"conditions":4155,"interventions":4156},"NCT02015871","An Extension Long-term Safety and Tolerability Trial of Degarelix in Chinese Patients With Prostate Cancer",[65],"2017-08-01","2014-01",[14],[1016],{"trials":4158,"activeCount":74},[4159],{"nctId":4160,"briefTitle":4161,"status":254,"phases":4162,"primaryCompletion":4163,"completion":4163,"start":4164,"enrollment":4165,"conditions":4166,"interventions":4167},"NCT02726009","A Trial to Evaluate Safety of Firmagon® (Degarelix) in Indian Patients Diagnosed With Advanced Hormone-dependent Prostate Cancer",[66],"2020-05-15","2016-05",230,[14],[1016],{"trials":4169,"activeCount":74},[4170,4180,4188,4198],{"nctId":4171,"briefTitle":4172,"status":254,"phases":4173,"primaryCompletion":4174,"completion":4175,"start":4176,"enrollment":4177,"conditions":4178,"interventions":4179},"NCT03193645","Observational Prospective Study Describing the Global Patient Care and Follow-up of Prostate Cancer Patients Treated With Degarelix",[],"2018-06-30","2019-01-31","2017-06-27",150,[14],[1016],{"nctId":4181,"briefTitle":4182,"status":254,"phases":4183,"primaryCompletion":4184,"completion":4184,"start":413,"enrollment":4185,"conditions":4186,"interventions":4187},"NCT02886598","Safety and Efficacy of Firmagon® (Degarelix) for Injection",[],"2019-03-26",368,[14],[3950],{"nctId":4189,"briefTitle":4190,"status":254,"phases":4191,"primaryCompletion":4192,"completion":4192,"start":2310,"enrollment":4193,"conditions":4194,"interventions":4196},"NCT02234089","Therapy Pathways in the Treatment of Hormone Naïve Prostate Cancer Patients With and Without Comorbidities Treated With Degarelix or Luteinizing-Hormone-Releasing-Hormone (LHRH) Agonists.",[],"2019-06-30",461,[4195],"Advanced Prostate Cancer",[1016,4197],"LHRH agonist",{"nctId":4199,"briefTitle":4200,"status":254,"phases":4201,"primaryCompletion":4202,"completion":4202,"start":2310,"enrollment":4203,"conditions":4204,"interventions":4206},"NCT02229253","Real-life Data of Cardiovascular Events Occuring During Degarelix Therapy for Prostate Cancer",[],"2017-10-04",112,[4205],"Advanced Hormone Sensitive Prostate Cancer",[3950],{"intervention":3336,"totalTrials":4208,"cells":4209},14,{"EARLY_PHASE1":4210,"PHASE1":4212,"PHASE2":4214,"PHASE3":4234,"PHASE4":4288,"NA":4290},{"trials":4211,"activeCount":74},[],{"trials":4213,"activeCount":74},[],{"trials":4215,"activeCount":74},[4216,4223,4227],{"nctId":4217,"briefTitle":4218,"status":254,"phases":4219,"primaryCompletion":325,"completion":325,"start":452,"enrollment":4220,"conditions":4221,"interventions":4222},"NCT01184859","Comparative Trial to Investigate the Dose-Response of 4 Different Dose Levels of Minirin Melt and Placebo",[64],116,[19],[3336],{"nctId":3329,"briefTitle":3330,"status":254,"phases":4224,"primaryCompletion":3332,"completion":3332,"start":3333,"enrollment":258,"conditions":4225,"interventions":4226},[64],[19],[3320,3336],{"nctId":4228,"briefTitle":4229,"status":543,"phases":4230,"primaryCompletion":4231,"completion":4231,"start":987,"enrollment":33,"conditions":4232,"interventions":4233},"NCT01779466","Daytime Impact Sleep Study",[64],"2014-06",[19],[3336],{"trials":4235,"activeCount":74},[4236,4244,4251,4258,4265,4273,4280],{"nctId":4237,"briefTitle":4238,"status":254,"phases":4239,"primaryCompletion":545,"completion":545,"start":4240,"enrollment":4241,"conditions":4242,"interventions":4243},"NCT01262456","Investigation of the Superiority Effect of Orally Disintegrating Desmopressin Tablets to Placebo in Terms of Night Voids Reduction in Nocturia Adult Male Patients",[65],"2011-02",395,[19],[3336],{"nctId":4245,"briefTitle":4246,"status":254,"phases":4247,"primaryCompletion":453,"completion":453,"start":439,"enrollment":4248,"conditions":4249,"interventions":4250},"NCT01078753","Study With Two Different Doses of Desmopressin Orally Lyophilisate Tablet With Nocturnal Enuresis",[65],89,[635],[3336],{"nctId":4252,"briefTitle":4253,"status":254,"phases":4254,"primaryCompletion":3680,"completion":3680,"start":413,"enrollment":4255,"conditions":4256,"interventions":4257},"NCT02905682","Trial of Desmopressin Orally Disintegrating Tablets (ODT) for Nocturia Due to Nocturnal Polyuria in Japanese Female Subjects",[65],190,[19],[3336],{"nctId":4259,"briefTitle":4260,"status":254,"phases":4261,"primaryCompletion":4093,"completion":894,"start":2611,"enrollment":1229,"conditions":4262,"interventions":4263},"NCT00230594","Desmopressin Response in the Young",[65],[855],[4264],"desmopressin",{"nctId":4266,"briefTitle":4267,"status":254,"phases":4268,"primaryCompletion":4269,"completion":4269,"start":413,"enrollment":4270,"conditions":4271,"interventions":4272},"NCT02904759","Trial of Desmopressin Orally Disintegrating Tablets (ODT) for Nocturia Due to Nocturnal Polyuria in Japanese Male Subjects",[65],"2017-09-29",342,[19],[3336],{"nctId":4274,"briefTitle":4275,"status":254,"phases":4276,"primaryCompletion":957,"completion":1860,"start":1193,"enrollment":4277,"conditions":4278,"interventions":4279},"NCT01552343","Study Investigating the Impact Burden of Nocturia Using the Nocturia Impact Diary",[65],56,[19],[3336],{"nctId":4281,"briefTitle":4282,"status":254,"phases":4283,"primaryCompletion":2462,"completion":2462,"start":4284,"enrollment":4285,"conditions":4286,"interventions":4287},"NCT01223937","Investigation of the Superiority Effect of Desmopressin to Placebo in Terms of Night Voids Reduction in Nocturia Adult Female Patients",[65],"2010-11",268,[19],[3336],{"trials":4289,"activeCount":74},[],{"trials":4291,"activeCount":74},[4292,4300,4310,4320],{"nctId":4293,"briefTitle":4294,"status":254,"phases":4295,"primaryCompletion":2463,"completion":2463,"start":1216,"enrollment":4296,"conditions":4297,"interventions":4299},"NCT00902265","Efficacy and Safety of Desmopressin (Nocturin®) 0.1 mg Tablets in Treatment of Nocturia in Participants With Benign Prostate Syndrome (BPS)",[],138,[4298],"Nocturia Associated With Nocturnal Polyuria",[4264],{"nctId":4301,"briefTitle":4302,"status":254,"phases":4303,"primaryCompletion":4304,"completion":4305,"start":969,"enrollment":4306,"conditions":4307,"interventions":4309},"NCT02368730","Documentation of the Efficacy of Desmopressin Within the Context of Surgical Procedures",[],"2016-06","2016-07",23,[4308],"Platelet Dysfunction",[4264],{"nctId":4311,"briefTitle":4312,"status":254,"phases":4313,"primaryCompletion":4314,"completion":4314,"start":4315,"enrollment":4316,"conditions":4317,"interventions":4319},"NCT04329975","Specified Drug Use-results Survey (Long-term Use) on MINIRINMELT® OD Tablet (Nocturia)",[],"2024-09-25","2020-05-19",1087,[4318],"Nocturia Due to Nocturnal Polyuria",[3336],{"nctId":4321,"briefTitle":4322,"status":543,"phases":4323,"primaryCompletion":4324,"completion":4324,"start":4325,"enrollment":4326,"conditions":4327,"interventions":4328},"NCT03089073","Study of Minirin Melt® in Adult Patients With Nocturia",[],"2018-10-05","2015-07-13",835,[19],[3336],{"intervention":353,"totalTrials":4330,"cells":4331},13,{"EARLY_PHASE1":4332,"PHASE1":4334,"PHASE2":4353,"PHASE3":4355,"PHASE4":4395,"NA":4397},{"trials":4333,"activeCount":74},[],{"trials":4335,"activeCount":74},[4336,4340,4349],{"nctId":3743,"briefTitle":3744,"status":543,"phases":4337,"primaryCompletion":3746,"completion":3746,"start":3747,"enrollment":3748,"conditions":4338,"interventions":4339},[63],[2015],[366,3736,3751],{"nctId":4341,"briefTitle":4342,"status":254,"phases":4343,"primaryCompletion":4344,"completion":4345,"start":4346,"enrollment":1173,"conditions":4347,"interventions":4348},"NCT04150861","Rekovelle PK Trial in Chinese Women",[63],"2019-11-28","2019-12-16","2019-06-23",[16],[353],{"nctId":2703,"briefTitle":2704,"status":543,"phases":4350,"primaryCompletion":2706,"completion":2706,"start":2707,"enrollment":2708,"conditions":4351,"interventions":4352},[63],[16],[2696,366],{"trials":4354,"activeCount":74},[],{"trials":4356,"activeCount":74},[4357,4361,4370,4374,4378,4387,4391],{"nctId":423,"briefTitle":424,"status":254,"phases":4358,"primaryCompletion":426,"completion":427,"start":428,"enrollment":429,"conditions":4359,"interventions":4360},[65],[16],[366,400],{"nctId":4362,"briefTitle":4363,"status":254,"phases":4364,"primaryCompletion":4365,"completion":4365,"start":4366,"enrollment":4367,"conditions":4368,"interventions":4369},"NCT03738618","Recombinant FSH Investigation in the Treatment of Infertility With Assisted Reproductive Technology (ART) (RITA-2)",[65],"2020-12-21","2018-10-29",588,[28],[366],{"nctId":344,"briefTitle":345,"status":254,"phases":4371,"primaryCompletion":347,"completion":348,"start":349,"enrollment":350,"conditions":4372,"interventions":4373},[65],[16],[353,333],{"nctId":355,"briefTitle":356,"status":254,"phases":4375,"primaryCompletion":358,"completion":359,"start":360,"enrollment":361,"conditions":4376,"interventions":4377},[65],[363],[365,366],{"nctId":4379,"briefTitle":4380,"status":254,"phases":4381,"primaryCompletion":4382,"completion":4382,"start":4383,"enrollment":4384,"conditions":4385,"interventions":4386},"NCT03740737","Recombinant FSH Investigation in the Treatment of Infertility With Assisted Reproductive Technology (ART) (RITA-1)",[65],"2020-11-11","2018-10-26",579,[16],[366],{"nctId":368,"briefTitle":369,"status":254,"phases":4388,"primaryCompletion":347,"completion":348,"start":371,"enrollment":372,"conditions":4389,"interventions":4390},[65],[16],[353,333],{"nctId":376,"briefTitle":377,"status":254,"phases":4392,"primaryCompletion":379,"completion":379,"start":380,"enrollment":381,"conditions":4393,"interventions":4394},[65],[16],[353,333],{"trials":4396,"activeCount":74},[],{"trials":4398,"activeCount":74},[4399,4409,4417],{"nctId":4400,"briefTitle":4401,"status":254,"phases":4402,"primaryCompletion":4403,"completion":4404,"start":4405,"enrollment":4406,"conditions":4407,"interventions":4408},"NCT03393780","Study to Assess the Patterns of Use of REKOVELLE® in Naïve Women Undergoing In Vitro Fertilisation or Intracytoplasmic Sperm Injection Procedures",[],"2020-04-17","2020-07-17","2018-03-16",1018,[32],[353],{"nctId":4410,"briefTitle":4411,"status":543,"phases":4412,"primaryCompletion":4413,"completion":4413,"start":4414,"enrollment":1510,"conditions":4415,"interventions":4416},"NCT03697031","Impact of Blastocyst Morphological Development and Blastocoele Re-expansion on Pregnancy Outcome After Using REKOVELLE®",[],"2020-12-31","2018-09-01",[32],[353],{"nctId":4418,"briefTitle":4419,"status":254,"phases":4420,"primaryCompletion":4421,"completion":4421,"start":4422,"enrollment":101,"conditions":4423,"interventions":4424},"NCT04503707","Study to Assess the Design of Use of REKOVELLE® in Women Undergoing In Vitro Fertilisation or Intracytoplasmic Sperm Injection Procedures in Routine Clinical Practice",[],"2021-10-31","2020-06-17",[32],[353],{"intervention":396,"totalTrials":70,"cells":4426},{"EARLY_PHASE1":4427,"PHASE1":4429,"PHASE2":4431,"PHASE3":4433,"PHASE4":4435,"NA":4445},{"trials":4428,"activeCount":74},[],{"trials":4430,"activeCount":74},[],{"trials":4432,"activeCount":74},[],{"trials":4434,"activeCount":74},[],{"trials":4436,"activeCount":74},[4437,4441],{"nctId":387,"briefTitle":388,"status":254,"phases":4438,"primaryCompletion":390,"completion":391,"start":392,"enrollment":393,"conditions":4439,"interventions":4440},[66],[16],[396,365],{"nctId":767,"briefTitle":768,"status":254,"phases":4442,"primaryCompletion":770,"completion":771,"start":479,"enrollment":772,"conditions":4443,"interventions":4444},[66],[16],[396,754,775,776,777],{"trials":4446,"activeCount":74},[4447,4455],{"nctId":4448,"briefTitle":4449,"status":254,"phases":4450,"primaryCompletion":4451,"completion":4451,"start":4304,"enrollment":4452,"conditions":4453,"interventions":4454},"NCT02835469","A Study on Efficacy and Safety of Menopur® Multidose in Korean Female Patients With Infertility",[],"2019-02-01",412,[16],[396],{"nctId":4456,"briefTitle":4457,"status":254,"phases":4458,"primaryCompletion":4459,"completion":4460,"start":4461,"enrollment":4462,"conditions":4463,"interventions":4464},"NCT02935335","A Study to Measure Relationship Between Antimüllerian Hormone and Initial Dose of Menopur®",[],"2018-01-31","2018-06-19","2016-10",297,[16],[396],{"intervention":4466,"totalTrials":70,"cells":4467},"mesalazine",{"EARLY_PHASE1":4468,"PHASE1":4470,"PHASE2":4472,"PHASE3":4474,"PHASE4":4486,"NA":4488},{"trials":4469,"activeCount":74},[],{"trials":4471,"activeCount":74},[],{"trials":4473,"activeCount":74},[],{"trials":4475,"activeCount":74},[4476,4480],{"nctId":1470,"briefTitle":1471,"status":254,"phases":4477,"primaryCompletion":1473,"completion":1474,"start":1475,"enrollment":1476,"conditions":4478,"interventions":4479},[65],[1478],[1450,1450,1480],{"nctId":4481,"briefTitle":4482,"status":543,"phases":4483,"primaryCompletion":1380,"completion":571,"start":1216,"enrollment":465,"conditions":4484,"interventions":4485},"NCT00245505","The Effect on Mucosal Healing With Pentasa Sachet in Mild to Moderate Active \"Drug: Crohn's Disease\"",[65],[30],[1480],{"trials":4487,"activeCount":74},[],{"trials":4489,"activeCount":74},[4490,4498],{"nctId":4491,"briefTitle":4492,"status":254,"phases":4493,"primaryCompletion":4494,"completion":4494,"start":4495,"enrollment":4177,"conditions":4496,"interventions":4497},"NCT02261636","Induction and Maintenance of Remission With Pentasa as Ulcerative Colitis Treatment",[],"2019-01-14","2015-01",[22],[4466],{"nctId":4499,"briefTitle":4500,"status":254,"phases":4501,"primaryCompletion":4502,"completion":4503,"start":499,"enrollment":4504,"conditions":4505,"interventions":4507},"NCT02368743","QUality of Life in pAtients With Mild to modeRate Active procTitis Treated by mesalaZine (Pentasa®)",[],"2017-03","2018-01-02",117,[4506],"Distal Ulcerative Colitis",[4466],{"intervention":589,"totalTrials":70,"cells":4509},{"EARLY_PHASE1":4510,"PHASE1":4512,"PHASE2":4514,"PHASE3":4516,"PHASE4":4518,"NA":4532},{"trials":4511,"activeCount":74},[],{"trials":4513,"activeCount":74},[],{"trials":4515,"activeCount":74},[],{"trials":4517,"activeCount":74},[],{"trials":4519,"activeCount":74},[4520,4524,4528],{"nctId":580,"briefTitle":581,"status":254,"phases":4521,"primaryCompletion":583,"completion":584,"start":585,"enrollment":586,"conditions":4522,"interventions":4523},[66],[16],[589,556],{"nctId":435,"briefTitle":436,"status":254,"phases":4525,"primaryCompletion":438,"completion":439,"start":440,"enrollment":441,"conditions":4526,"interventions":4527},[66],[16],[444,445,419,446,447],{"nctId":449,"briefTitle":450,"status":254,"phases":4529,"primaryCompletion":452,"completion":453,"start":454,"enrollment":455,"conditions":4530,"interventions":4531},[66],[457,16],[444,459,400,446,460],{"trials":4533,"activeCount":74},[4534],{"nctId":4535,"briefTitle":4536,"status":254,"phases":4537,"primaryCompletion":4538,"completion":4539,"start":4154,"enrollment":4540,"conditions":4541,"interventions":4542},"NCT02018159","An Explorative Prospective Observational Study to Describe Morphokinetic De-selection Parameters in Human Embryos",[],"2016-02-12","2016-05-12",738,[16],[589],{"intervention":4544,"totalTrials":465,"cells":4545},"Somatropin",{"EARLY_PHASE1":4546,"PHASE1":4548,"PHASE2":4550,"PHASE3":4552,"PHASE4":4554,"NA":4556},{"trials":4547,"activeCount":74},[],{"trials":4549,"activeCount":74},[],{"trials":4551,"activeCount":74},[],{"trials":4553,"activeCount":74},[],{"trials":4555,"activeCount":74},[],{"trials":4557,"activeCount":74},[4558,4566,4574],{"nctId":4559,"briefTitle":4560,"status":114,"phases":4561,"primaryCompletion":4562,"completion":4563,"start":770,"enrollment":74,"conditions":4564,"interventions":4565},"NCT01731028","Surveillance of Treatment of Children With Growth Hormone Deficiency With Zomacton®",[],"2017-12","2018-06",[2057],[4544],{"nctId":4567,"briefTitle":4568,"status":543,"phases":4569,"primaryCompletion":500,"completion":500,"start":970,"enrollment":465,"conditions":4570,"interventions":4572},"NCT02018172","Evaluation of the Adherence and the Patient Acceptability of Zomacton® Treatment With the Zomajet® Vision X Device",[],[2057,4571],"Turner's Syndrome",[4573],"somatropin",{"nctId":4575,"briefTitle":4576,"status":254,"phases":4577,"primaryCompletion":2161,"completion":2462,"start":4578,"enrollment":4579,"conditions":4580,"interventions":4582},"NCT01306357","Evaluation of Overall Compliance and Duration of Zomacton® Treatment With the Zomajet® Needle-free Device",[],"2007-09",87,[4571,4581],"Human Growth Hormone Deficiency",[4544],{"intervention":4584,"totalTrials":465,"cells":4585},"hMG-HP",{"EARLY_PHASE1":4586,"PHASE1":4588,"PHASE2":4590,"PHASE3":4592,"PHASE4":4594,"NA":4596},{"trials":4587,"activeCount":74},[],{"trials":4589,"activeCount":74},[],{"trials":4591,"activeCount":74},[],{"trials":4593,"activeCount":74},[],{"trials":4595,"activeCount":74},[],{"trials":4597,"activeCount":74},[4598,4606,4614],{"nctId":4599,"briefTitle":4600,"status":254,"phases":4601,"primaryCompletion":390,"completion":2664,"start":315,"enrollment":4602,"conditions":4603,"interventions":4605},"NCT01330784","Assessment of the Therapeutic Utility of hMG-HP",[],61,[4604],"Sterility",[4584],{"nctId":4607,"briefTitle":4608,"status":254,"phases":4609,"primaryCompletion":3121,"completion":452,"start":2665,"enrollment":4610,"conditions":4611,"interventions":4613},"NCT01331720","Assessment of the Effectiveness and Tolerability of Ovarian Hyperstimulation",[],279,[4612],"STERILITY",[4584],{"nctId":4615,"briefTitle":4616,"status":254,"phases":4617,"primaryCompletion":4618,"completion":3121,"start":298,"enrollment":3974,"conditions":4619,"interventions":4620},"NCT01331733","Comparative Assessment of the Clinical Utility of Ovarian Stimulation With Menotropin Versus Menotropin Plus GnRH Antagonist",[],"2008-10",[4604],[4584,4621],"hMG + GnRH antagonist",{"intervention":2059,"totalTrials":465,"cells":4623},{"EARLY_PHASE1":4624,"PHASE1":4626,"PHASE2":4628,"PHASE3":4630,"PHASE4":4644,"NA":4646},{"trials":4625,"activeCount":74},[],{"trials":4627,"activeCount":74},[],{"trials":4629,"activeCount":74},[],{"trials":4631,"activeCount":74},[4632,4636],{"nctId":2052,"briefTitle":2053,"status":254,"phases":4633,"primaryCompletion":1860,"completion":989,"start":439,"enrollment":2055,"conditions":4634,"interventions":4635},[65],[2057],[2041,2059],{"nctId":4637,"briefTitle":4638,"status":254,"phases":4639,"primaryCompletion":3972,"completion":2995,"start":392,"enrollment":4640,"conditions":4641,"interventions":4642},"NCT00250250","An Open-Label, Multi-centre, Phase III Study of Local Tolerability of ZOMACTON 10MG",[65],27,[4571],[4643],"ZOMACTON",{"trials":4645,"activeCount":74},[],{"trials":4647,"activeCount":74},[4648],{"nctId":4649,"briefTitle":4650,"status":543,"phases":4651,"primaryCompletion":4652,"completion":4652,"start":2879,"enrollment":70,"conditions":4653,"interventions":4655},"NCT03274973","Study to Assess Long-term Effectiveness of Zomacton® and Treatment Adherence in Patients With Growth Hormone Deficiency or Ullrich-Turner Syndrome",[],"2018-10-31",[4654],"Growth Disorders",[2059],{"intervention":4657,"totalTrials":108,"cells":4658},"Sodium Picosulfate, Magnesium Oxide and Citric Acid",{"EARLY_PHASE1":4659,"PHASE1":4661,"PHASE2":4663,"PHASE3":4665,"PHASE4":4667,"NA":4673},{"trials":4660,"activeCount":74},[],{"trials":4662,"activeCount":74},[],{"trials":4664,"activeCount":74},[],{"trials":4666,"activeCount":74},[],{"trials":4668,"activeCount":74},[4669],{"nctId":496,"briefTitle":497,"status":254,"phases":4670,"primaryCompletion":499,"completion":499,"start":500,"enrollment":501,"conditions":4671,"interventions":4672},[66],[214],[504,505,506],{"trials":4674,"activeCount":74},[4675],{"nctId":4676,"briefTitle":4677,"status":254,"phases":4678,"primaryCompletion":4679,"completion":4679,"start":4680,"enrollment":4681,"conditions":4682,"interventions":4683},"NCT03631446","Drug Use-Results Survey on Picoprep® Combination Powder",[],"2021-12-31","2017-08-29",1298,[1128],[4657],{"intervention":4685,"totalTrials":108,"cells":4686},"ADSTILADRIN",{"EARLY_PHASE1":4687,"PHASE1":4689,"PHASE2":4691,"PHASE3":4693,"PHASE4":4705,"NA":4707},{"trials":4688,"activeCount":74},[],{"trials":4690,"activeCount":74},[],{"trials":4692,"activeCount":74},[],{"trials":4694,"activeCount":74},[4695],{"nctId":4696,"briefTitle":4697,"status":254,"phases":4698,"primaryCompletion":4699,"completion":4700,"start":4701,"enrollment":2464,"conditions":4702,"interventions":4704},"NCT02773849","ADSTILADRIN (=INSTILADRIN) in Patients With High-Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)",[65],"2019-05-24","2023-05-24","2016-09-19",[4703],"Superficial Bladder Cancer",[4685],{"trials":4706,"activeCount":74},[],{"trials":4708,"activeCount":74},[4709],{"nctId":4710,"briefTitle":4711,"status":543,"phases":4712,"primaryCompletion":3704,"completion":3704,"start":4713,"enrollment":4714,"conditions":4715,"interventions":4716},"NCT06026332","ADSTILADRIN Early Utilization and Outcomes in the Real World Setting",[],"2023-09-15",202,[119],[4685],{"intervention":4718,"totalTrials":108,"cells":4719},"misoprostol",{"EARLY_PHASE1":4720,"PHASE1":4722,"PHASE2":4724,"PHASE3":4734,"PHASE4":4736,"NA":4738},{"trials":4721,"activeCount":74},[],{"trials":4723,"activeCount":74},[],{"trials":4725,"activeCount":74},[4726],{"nctId":4727,"briefTitle":4728,"status":254,"phases":4729,"primaryCompletion":4284,"completion":4284,"start":439,"enrollment":4730,"conditions":4731,"interventions":4733},"NCT00925938","Efficacy and Safety Study of the Misoprostol Vaginal Priming Insert (MVPI) Prior to Hysteroscopy",[64],51,[4732],"Cervical Priming",[4718],{"trials":4735,"activeCount":74},[],{"trials":4737,"activeCount":74},[],{"trials":4739,"activeCount":74},[4740],{"nctId":4741,"briefTitle":4742,"status":254,"phases":4743,"primaryCompletion":1533,"completion":1533,"start":2310,"enrollment":2708,"conditions":4744,"interventions":4746},"NCT02242214","REgistry of MisOprostol 200 µg Vaginal dElivery System",[],[4745],"Induction of Labour",[4747],"Misoprostol",{"intervention":4749,"totalTrials":87,"cells":4750},"budesonide MMX®",{"EARLY_PHASE1":4751,"PHASE1":4753,"PHASE2":4755,"PHASE3":4757,"PHASE4":4759,"NA":4761},{"trials":4752,"activeCount":74},[],{"trials":4754,"activeCount":74},[],{"trials":4756,"activeCount":74},[],{"trials":4758,"activeCount":74},[],{"trials":4760,"activeCount":74},[],{"trials":4762,"activeCount":74},[4763],{"nctId":4764,"briefTitle":4765,"status":254,"phases":4766,"primaryCompletion":4767,"completion":4767,"start":499,"enrollment":4768,"conditions":4769,"interventions":4770},"NCT02586259","Effectiveness of Cortiment® in Patients With Ulcerative Colitis",[],"2018-04-05",378,[22],[4749],{"intervention":4772,"totalTrials":87,"cells":4773},"hMG",{"EARLY_PHASE1":4774,"PHASE1":4776,"PHASE2":4778,"PHASE3":4780,"PHASE4":4782,"NA":4784},{"trials":4775,"activeCount":74},[],{"trials":4777,"activeCount":74},[],{"trials":4779,"activeCount":74},[],{"trials":4781,"activeCount":74},[],{"trials":4783,"activeCount":74},[],{"trials":4785,"activeCount":74},[4786],{"nctId":4787,"briefTitle":4788,"status":254,"phases":4789,"primaryCompletion":4790,"completion":1417,"start":1402,"enrollment":4791,"conditions":4792,"interventions":4793},"NCT01354834","Assessment of the Effectiveness of Menopur in Intrauterine Insemination",[],"2005-12",207,[16],[4772],{"intervention":4795,"totalTrials":87,"cells":4796},"REKOVELLE®",{"EARLY_PHASE1":4797,"PHASE1":4799,"PHASE2":4801,"PHASE3":4803,"PHASE4":4805,"NA":4807},{"trials":4798,"activeCount":74},[],{"trials":4800,"activeCount":74},[],{"trials":4802,"activeCount":74},[],{"trials":4804,"activeCount":74},[],{"trials":4806,"activeCount":74},[],{"trials":4808,"activeCount":74},[4809],{"nctId":4810,"briefTitle":4811,"status":254,"phases":4812,"primaryCompletion":4813,"completion":4813,"start":4814,"enrollment":4815,"conditions":4816,"interventions":4817},"NCT05499052","Trial to Assess the Pattern of Use of REKOVELLE® in Women Undergoing In Vitro Fertilisation (IVF) or Intracytoplasmic Sperm Injection (ICSI) Procedures in Routine Clinical Practice",[],"2024-03-14","2022-08-28",201,[32],[4795],{"intervention":4819,"totalTrials":87,"cells":4820},"Degarelix or GnRH agonist",{"EARLY_PHASE1":4821,"PHASE1":4823,"PHASE2":4825,"PHASE3":4827,"PHASE4":4829,"NA":4831},{"trials":4822,"activeCount":74},[],{"trials":4824,"activeCount":74},[],{"trials":4826,"activeCount":74},[],{"trials":4828,"activeCount":74},[],{"trials":4830,"activeCount":74},[],{"trials":4832,"activeCount":74},[4833],{"nctId":4834,"briefTitle":4835,"status":254,"phases":4836,"primaryCompletion":1598,"completion":1598,"start":988,"enrollment":4837,"conditions":4838,"interventions":4839},"NCT01729676","Impact of the Geographical FACTor on the Prostate Cancer Stage at Hormonal Therapy Initiation",[],315,[14],[4819],{"intervention":4841,"totalTrials":87,"cells":4842},"Growth Hormone",{"EARLY_PHASE1":4843,"PHASE1":4845,"PHASE2":4847,"PHASE3":4849,"PHASE4":4851,"NA":4853},{"trials":4844,"activeCount":74},[],{"trials":4846,"activeCount":74},[],{"trials":4848,"activeCount":74},[],{"trials":4850,"activeCount":74},[],{"trials":4852,"activeCount":74},[],{"trials":4854,"activeCount":74},[4855],{"nctId":4856,"briefTitle":4857,"status":254,"phases":4858,"primaryCompletion":4859,"completion":4860,"start":1509,"enrollment":4861,"conditions":4862,"interventions":4863},"NCT01351818","Adipocyte Function and Somtropin Deficiency",[],"2008-01","2008-03",62,[2057],[4841],{"intervention":4197,"totalTrials":87,"cells":4865},{"EARLY_PHASE1":4866,"PHASE1":4868,"PHASE2":4870,"PHASE3":4872,"PHASE4":4874,"NA":4876},{"trials":4867,"activeCount":74},[],{"trials":4869,"activeCount":74},[],{"trials":4871,"activeCount":74},[],{"trials":4873,"activeCount":74},[],{"trials":4875,"activeCount":74},[],{"trials":4877,"activeCount":74},[4878],{"nctId":4189,"briefTitle":4190,"status":254,"phases":4879,"primaryCompletion":4192,"completion":4192,"start":2310,"enrollment":4193,"conditions":4880,"interventions":4881},[],[4195],[1016,4197],{"intervention":4883,"totalTrials":87,"cells":4884},"sodium picosulphate",{"EARLY_PHASE1":4885,"PHASE1":4887,"PHASE2":4889,"PHASE3":4891,"PHASE4":4893,"NA":4895},{"trials":4886,"activeCount":74},[],{"trials":4888,"activeCount":74},[],{"trials":4890,"activeCount":74},[],{"trials":4892,"activeCount":74},[],{"trials":4894,"activeCount":74},[],{"trials":4896,"activeCount":74},[4897],{"nctId":4898,"briefTitle":4899,"status":254,"phases":4900,"primaryCompletion":1012,"completion":4901,"start":2684,"enrollment":4902,"conditions":4903,"interventions":4905},"NCT01292109","A Study of PICOPREP in Patients Needed to Clean the Bowel Prior to X-ray Examination, Endoscopy or Surgery.",[],"2012-02",252,[4904],"Bowel Cleanliness",[4883],{"intervention":4907,"totalTrials":87,"cells":4908},"Firmagon®",{"EARLY_PHASE1":4909,"PHASE1":4911,"PHASE2":4913,"PHASE3":4915,"PHASE4":4917,"NA":4919},{"trials":4910,"activeCount":74},[],{"trials":4912,"activeCount":74},[],{"trials":4914,"activeCount":74},[],{"trials":4916,"activeCount":74},[],{"trials":4918,"activeCount":74},[],{"trials":4920,"activeCount":74},[4921],{"nctId":4922,"briefTitle":4923,"status":254,"phases":4924,"primaryCompletion":4925,"completion":4925,"start":1058,"enrollment":4926,"conditions":4927,"interventions":4929},"NCT01861236","Effectiveness and Safety of Firmagon® in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma in Argentina",[],"2018-09-03",90,[4928],"Advanced Hormone Dependent Prostate Cancer",[4907],{"intervention":4621,"totalTrials":87,"cells":4931},{"EARLY_PHASE1":4932,"PHASE1":4934,"PHASE2":4936,"PHASE3":4938,"PHASE4":4940,"NA":4942},{"trials":4933,"activeCount":74},[],{"trials":4935,"activeCount":74},[],{"trials":4937,"activeCount":74},[],{"trials":4939,"activeCount":74},[],{"trials":4941,"activeCount":74},[],{"trials":4943,"activeCount":74},[4944],{"nctId":4615,"briefTitle":4616,"status":254,"phases":4945,"primaryCompletion":4618,"completion":3121,"start":298,"enrollment":3974,"conditions":4946,"interventions":4947},[],[4604],[4584,4621],{"intervention":4949,"totalTrials":87,"cells":4950},"hMG-HP\u002Fr-FSH",{"EARLY_PHASE1":4951,"PHASE1":4953,"PHASE2":4955,"PHASE3":4957,"PHASE4":4959,"NA":4961},{"trials":4952,"activeCount":74},[],{"trials":4954,"activeCount":74},[],{"trials":4956,"activeCount":74},[],{"trials":4958,"activeCount":74},[],{"trials":4960,"activeCount":74},[],{"trials":4962,"activeCount":74},[4963],{"nctId":4964,"briefTitle":4965,"status":254,"phases":4966,"primaryCompletion":4967,"completion":2664,"start":315,"enrollment":4730,"conditions":4968,"interventions":4969},"NCT01330771","Assessment of the Therapeutic Utility of r-FSH in Association With hMG-HP",[],"2008-06",[4604],[4949],{"intervention":4971,"totalTrials":87,"cells":4972},"REBYOTA™",{"EARLY_PHASE1":4973,"PHASE1":4975,"PHASE2":4977,"PHASE3":4979,"PHASE4":4981,"NA":4983},{"trials":4974,"activeCount":74},[],{"trials":4976,"activeCount":74},[],{"trials":4978,"activeCount":74},[],{"trials":4980,"activeCount":74},[],{"trials":4982,"activeCount":74},[],{"trials":4984,"activeCount":74},[4985],{"nctId":4986,"briefTitle":4987,"status":254,"phases":4988,"primaryCompletion":4989,"completion":4989,"start":4990,"enrollment":980,"conditions":4991,"interventions":4993},"NCT05835219","REBYOTA™ Prospective Registry",[],"2025-08-29","2023-06-19",[4992],"Recurrence of Clostridium Difficile Infection",[4971]]